var title_f8_16_8448="Contents: Hypertension";
var content_f8_16_8448=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hypertension",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hypertension",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Definition and types",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43080\">",
"           Blood pressure measurement in the diagnosis and management of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/422\">",
"           Initial evaluation of the hypertensive adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1543\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29737\">",
"           Blood pressure management in patients with atherosclerotic cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18068\">",
"           Can therapy be discontinued in well-controlled hypertension?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20218\">",
"           Choice of therapy in essential hypertension: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36314\">",
"           Choice of therapy in primary (essential) hypertension: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36728\">",
"           Definition, risk factors, and evaluation of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/14/19685\">",
"           Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4169\">",
"           Hypertension: Who should be treated?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32966\">",
"           Major side effects and safety of calcium channel blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18473\">",
"           Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23828\">",
"           Patient adherence and the treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33046\">",
"           Perioperative management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/60/19398\">",
"           Renal effects of ACE inhibitors in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25224\">",
"           Renin-angiotensin system inhibition in the treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/41/4755\">",
"           The prevalence and control of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13027\">",
"           Thiazides versus loop diuretics in treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/62/2021\">",
"           Treatment of hypertension in asthma and COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/14/15592\">",
"           Treatment of hypertension in blacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21210\">",
"           Treatment of hypertension in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35256\">",
"           Treatment of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15350\">",
"           Use of thiazide diuretics in patients with primary hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14149\">",
"           Vasopeptidase inhibition in the management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/40/33417\">",
"           What is goal blood pressure in the treatment of hypertension?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1827\">",
"           Withdrawal syndromes with antihypertensive therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         End-organ damage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36825\">",
"           Actions of angiotensin II on the heart",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37685\">",
"           Cardiovascular risks of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/42/6824\">",
"           Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17959\">",
"           Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18247\">",
"           Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20261\">",
"           Effect of antihypertensive treatment on renal function in essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3285\">",
"           Electrocardiographic diagnosis of left ventricular hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/23/1401\">",
"           Left ventricular hypertrophy and arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21859\">",
"           Ocular effects of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37859\">",
"           Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/23/16761\">",
"           Hypertension after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8436\">",
"           Hypertension following erythropoietin in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30582\">",
"           Hypertension in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/46/20202\">",
"           Hypertension in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36804\">",
"           Low-renin essential (primary) hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42674\">",
"           NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/61/34770\">",
"           Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7337\">",
"           Overview of hypertension in acute and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38874\">",
"           Overview of the risks and benefits of alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39477\">",
"           Possible role of low birth weight in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertensive emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28246\">",
"           Management of severe asymptomatic hypertension (hypertensive urgencies)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Monitoring",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7113\">",
"           Ambulatory blood pressure monitoring and white coat hypertension in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonpharmacologic therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/30/38375\">",
"           Cardiovascular effects of caffeine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42679\">",
"           Diet in the treatment and prevention of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8345\">",
"           Dietary therapy for obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33866\">",
"           Drug therapy of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/2998\">",
"           Exercise in the treatment and prevention of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34630\">",
"           Obesity and weight reduction in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13060\">",
"           Potassium and hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/35/24120\">",
"           Salt intake, salt restriction, and essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3395\">",
"           Smoking and hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/63/3060\">",
"           Essential hypertension in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11174\">",
"           Hypertensive complications in blacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26823\">",
"           Increased pulse pressure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44677\">",
"           Prehypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Resistant hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36728\">",
"           Definition, risk factors, and evaluation of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35256\">",
"           Treatment of resistant hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Secondary hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33433\">",
"           Chronic kidney disease associated with atherosclerotic renovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34471\">",
"           Clinical manifestations and diagnosis of fibromuscular dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/31001\">",
"           Establishing the diagnosis of renovascular hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7544\">",
"           Evaluation of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36214\">",
"           Paroxysmal hypertension (pseudopheochromocytoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28503\">",
"           Pathophysiology of cardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/54/21351\">",
"           Pheochromocytoma in genetic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/54/8040\">",
"           Treatment of bilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26631\">",
"           Treatment of fibromuscular dysplasia of the renal arteries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/54/32616\">",
"           Treatment of pheochromocytoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29369\">",
"           Treatment of unilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/21/27991\">",
"           Who should be evaluated for renovascular or other causes of secondary hypertension?",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D4FB1588E8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_16_8448=[""].join("\n");
var outline_f8_16_8448=null;
var title_f8_16_8449="Circumscribed morphea - chest";
var content_f8_16_8449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumscribed morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A shiny, slightly hyperpigmented, indurated oval plaque is present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8449=[""].join("\n");
var outline_f8_16_8449=null;
var title_f8_16_8450="Scimitar syndrome II";
var content_f8_16_8450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scimitar syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows an abnormal right basilar draining vein as well as dilated central pulmonary arteries due to pulmonary arterial hypertension from longstanding left-to-right shunt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8450=[""].join("\n");
var outline_f8_16_8450=null;
var title_f8_16_8451="Patient information: Atrial flutter (The Basics)";
var content_f8_16_8451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83438\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"           Person having a stress test",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"            Signs of stroke",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/36/17986\">",
"         Patient information: Medicines for atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/54/13154\">",
"         Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/34/5666\">",
"         Patient information: Tachycardia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/10/24738\">",
"         Patient information: Cardioversion (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/16/20741\">",
"         Patient information: Pacemakers (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/31/14834\">",
"         Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/9/4245\">",
"         Patient information: Syncope (fainting) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Atrial flutter (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/atrial-flutter-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H154416358\">",
"      <span class=\"h1\">",
"       What is atrial flutter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atrial flutter is a heart problem in which the heart beats much faster than normal. Atrial flutter puts people at risk for stroke and other problems.",
"     </p>",
"     <p>",
"      In atrial flutter, the electrical signals that control the heartbeat become abnormal. As a result, the heart&rsquo;s upper chambers stop pumping effectively. Blood that should move out of these chambers gets left behind. As the blood pools, it can start to form clots. These clots can travel up to the brain through the blood vessels, and cause strokes.",
"     </p>",
"     <p>",
"      Atrial flutter happens most often in people who had recent heart surgery or who have certain heart conditions, such as a heart valve problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H154416373\">",
"      <span class=\"h1\">",
"       What are the symptoms of atrial flutter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms. When symptoms do happen, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling like your heart is beating fast, beating hard, or skipping beats",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Feeling light-headed or dizzy",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Fainting, or feeling like you are going to faint",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H154416388\">",
"      <span class=\"h1\">",
"       Is there a test for atrial flutter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;), which measures the electrical activity in your heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Your doctor will also do other tests to look for heart problems that could be causing your atrial flutter. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        An echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of the heart as it beats (",
"        <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        An exercise stress test &ndash; During this test, the doctor will record your ECG while you exercise on a treadmill or bike (",
"        <a class=\"graphic graphic_figure graphicRef60855 \" href=\"UTD.htm?31/21/32085\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A home heart monitor &ndash; This test records your heartbeat over the course of hours or days.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H154416403\">",
"      <span class=\"h1\">",
"       How is atrial flutter treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and what&rsquo;s causing your atrial flutter.",
"     </p>",
"     <p>",
"      People who have no symptoms might not need treatment. This is because atrial flutter sometimes changes back to a normal heart rhythm without treatment (after days or weeks).",
"     </p>",
"     <p>",
"      When treatment is needed, it can include 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to change the heart rhythm back to normal, or control the speed or rhythm of the heartbeat",
"       </li>",
"       <li>",
"        Medicines to prevent blood clots from forming",
"       </li>",
"       <li>",
"        Cardioversion &ndash; During this procedure, the doctor gives the heart a mild electrical current to change the rhythm back to normal.",
"       </li>",
"       <li>",
"        Ablation &ndash; During this procedure, the doctor uses heat or cold to destroy the small part of the heart that is sending the abnormal electrical signals.",
"       </li>",
"       <li>",
"        A pacemaker &ndash; This is a device that goes under the skin near a person&rsquo;s heart. It sends electrical signals to the heart to control the heartbeat.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H154416418\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with atrial flutter are able to live fairly normal lives. Still, it is important that you take your medicines every day, as prescribed by your doctor. Taking your medicines will help lower the chances that your atrial flutter will cause a stroke. Even so, it&rsquo;s a good idea to learn the signs and symptoms of a stroke (",
"      <a class=\"graphic graphic_figure graphicRef73487 \" href=\"UTD.htm?21/2/21542\">",
"       figure 4",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H154416433\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=see_link\">",
"       Patient information: Medicines for atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"       Patient information: Tachycardia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"       Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       Patient information: Syncope (fainting) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       Patient information: Pacemakers (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"       Patient information: Cardioversion (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"       Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/16/8451?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83438 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8451=[""].join("\n");
var outline_f8_16_8451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416358\">",
"      What is atrial flutter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416373\">",
"      What are the symptoms of atrial flutter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416388\">",
"      Is there a test for atrial flutter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416403\">",
"      How is atrial flutter treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416418\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154416433\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"        Person having a stress test",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"         Signs of stroke",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=related_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=related_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8452="Fluocinonide: Patient drug information";
var content_f8_16_8452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluocinonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     see \"Fluocinonide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/1/9235?source=see_link\">",
"     see \"Fluocinonide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vanos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lidemol&reg;;",
"     </li>",
"     <li>",
"      Lidex&reg;;",
"     </li>",
"     <li>",
"      Lyderm&reg;;",
"     </li>",
"     <li>",
"      Tiamol&reg;;",
"     </li>",
"     <li>",
"      Topactin;",
"     </li>",
"     <li>",
"      Topsyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10356882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluocinonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3474102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very bad skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12481 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8452=[""].join("\n");
var outline_f8_16_8452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10356882\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016294\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016293\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016298\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016299\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016301\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016296\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016297\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016302\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016303\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=related_link\">",
"      Fluocinonide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/1/9235?source=related_link\">",
"      Fluocinonide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8453="Little brown mushrooms";
var content_f8_16_8453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Little brown mushrooms or backyard mushrooms: Lepiota naucina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One of the many types of \"little brown mushrooms\" found growing in backyards. Lepiota naucina are edible. These mushrooms are sometimes confused with Amanita virosa (and other Amanita species) resulting in severe toxicity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Dengler. Identification by William Hollenbaugh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8453=[""].join("\n");
var outline_f8_16_8453=null;
var title_f8_16_8454="Fluticasone and salmeterol: Patient drug information";
var content_f8_16_8454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluticasone and salmeterol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"     see \"Fluticasone and salmeterol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/53/23384?source=see_link\">",
"     see \"Fluticasone and salmeterol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When changing from an oral steroid to a breathed in one, there may be very bad and sometimes deadly side effects. Signs like weakness, feeling tired, dizziness, upset stomach, throwing up, not thinking clearly, or low blood sugar may happen. Call your doctor right away if you have any of these signs. If you have a bad injury, have surgery, or any type of infection, you may need extra doses of oral steroids. These extra steroids will help your body deal with these stresses. Carry a warning card saying that there may be times when you may need extra steroids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In patients with asthma, long-acting puffers (inhalers) raised asthma-related deaths. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 1 week to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702153",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluticasone, salmeterol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack. Use a rescue inhaler. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox or measles and have not had chickenpox or measles or had a chickenpox or measles vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake Advair&reg; HFA well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare puffer (inhaler) before first use or when puffer has not been used for more than 4 weeks. Spray 4 test sprays into the air.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Advair&reg; Diskus&reg;: Throw away any part not used after 1 month or when the indicator reads zero, whichever comes first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Advair&reg; HFA: Throw away when the indicator reads zero.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12493 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8454=[""].join("\n");
var outline_f8_16_8454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173433\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025020\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025022\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025021\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025026\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025027\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025029\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025024\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025025\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025030\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025031\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=related_link\">",
"      Fluticasone and salmeterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/53/23384?source=related_link\">",
"      Fluticasone and salmeterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8455="Phase contrast micrograph showing dysmorphic red cells in urine";
var content_f8_16_8455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79440%7ENEPH%2F62064%7ENEPH%2F55778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79440%7ENEPH%2F62064%7ENEPH%2F55778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phase contrast micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phase contrast microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scanning electron micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with a red cell cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing free red cells and a red cell cast that is tightly packed with red cells. It is more common for red cell casts to have fewer red cells trapped within a hyaline or granular cast. Red cell casts are virtually diagnostic of glomerulonephritis or vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8455=[""].join("\n");
var outline_f8_16_8455=null;
var title_f8_16_8456="Eye disorders associated with chronic kidney disease";
var content_f8_16_8456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eye disorders associated with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Eli A Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8456/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/16/8456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical supervision of patients with chronic kidney disease and end-stage renal disease (ESRD) seldom requires specific attention to the eyes. An important exception is the need for perpetual surveillance, in collaboration with an ophthalmologist, of all dialysis patients with diabetes, in whom the risk of vision loss is substantial.",
"   </p>",
"   <p>",
"    Disorders of the kidney rarely directly affect vision or change the anatomic integrity of the eyes. Recognition of a coincident eye problem during evaluation of kidney disease is usually fortuitous. As an example, advanced proliferative diabetic retinopathy can be completely asymptomatic. At the other extreme, complaints about vision may lead to the diagnosis of a previously unsuspected kidney disease. The presence of Alport syndrome, for example, may be detected when corneal erosion or anterior lenticonus is found during the assessment for blurred vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OPHTHALMOSCOPIC EVALUATION AND GENERAL FINDINGS IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive study of a patient with chronic kidney disease (CKD) or end-stage kidney disease (ESRD) should include examination of the external eye and direct ophthalmoscopy. Benefits of this approach were noted in a multicenter, cross-sectional longitudinal study of 1936 individuals with varying stages of CKD in which 45 degree digital photos of the disc and macula in both eyes, obtained by nonophthalmologic personnel, were assessed in a masked manner by a retinal specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/1\">",
"     1",
"    </a>",
"    ]. A total of 1904 subjects (98 percent) had satisfactory photographs of at least one eye, of whom eye &ldquo;pathologies&rdquo; requiring follow-up examination by an ophthalmologist were identified in 864 (45 percent). These pathologies included serious eye conditions requiring urgent treatment in 65 participants (3 percent) and diabetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertensive disease in 482 (25 percent). An estimated glomerular filtration rate (GFR) less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 was associated with a three times higher risk for retinopathy than a normal GFR.",
"   </p>",
"   <p>",
"    Advanced kidney disease of any etiology induces eye findings that signal the need for initiation or intensification of therapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctival erythema, termed the red eyes of uremia, may be noted when high plasma phosphate levels induce corneal and conjunctival precipitation of calcium pyrophosphate.",
"     </li>",
"     <li>",
"      Metastatic calcification in the eyes may be associated with elevations of the serum concentration of calcium or calcium-phosphate product [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Profound uremia may rarely be complicated by transient cortical blindness; this is termed uremic amaurosis, which occurs in association with preserved pupillary contraction on light exposure and normal fundoscopic findings. This abnormality clears within 24 to 48 hours of initiating dialytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/3\">",
"       3",
"      </a>",
"      ]. Evanescent cortical blindness has also been reported in kidney transplant recipients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and interferon [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections address issues related to the relationship between abnormal eye findings and end-stage renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Red eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;When maintenance hemodialysis was first introduced, conjunctival erythema was a common finding, due largely to the consequences of poor dialysis, phosphate retention, secondary hyperparathyroidism,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic calcification, with resultant corneal deposition of calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Among 57 dialysis patients, for example, 8 had erythema and calcium precipitation in the limboconjunctival area, while 3 of these showed diffuse eye inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/8\">",
"     8",
"    </a>",
"    ]. This last finding was characterized by a waxy red episcleral and conjunctival hyperemia extending beyond the palpebral fissure. Mean serum calcium concentration was significantly higher in those with red eyes than in patients without conjunctival redness.",
"   </p>",
"   <p>",
"    However, even with adequate hemodialysis, focal hyperemia may develop with surrounding deposition of calcium salts in the limboconjunctivae. Increasing severity of such deposition may be associated with multiple factors, including duration of dialysis, calcium-phosphorous product, parathyroid hormone levels, and the serum phosphorous concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pingueculae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of localized eye erythema associated with spots of yellowish-orange pigmentation, termed pingueculae, has been reported in patients undergoing maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/10\">",
"     10",
"    </a>",
"    ]. Pingueculae are benign peribulbar lesions that are composed of degenerated basophilic subepithelial tissue. They do not affect vision, and minor irritation can usually be managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of pinguecula is postulated to be due in part to exposure to dust, which is supported by an increased prevalence in motorcycle policemen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/12\">",
"     12",
"    </a>",
"    ]. Their association with hypercalcemia and localized calcium deposition suggests that other chronic irritations may provoke this purportedly benign reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cataracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataracts due to chronic hypocalcemia can be the presenting sign of otherwise asymptomatic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/13\">",
"     13",
"    </a>",
"    ]. Some investigators have also claimed an association between cataract formation and hypocalcemia among long-term dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, in an observational study of 20 dialysis patients for a period ranging from 4 to 53 months, only one individual manifested bilateral anterior and posterior subcapsular cataracts. These findings are suggestive of hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age-related macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;While diabetes is generally ranked as the leading cause of adult blindness in industrialized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/17\">",
"     17",
"    </a>",
"    ], age-related macular degeneration (AMD) is a leading cause of vision loss in Americans 60 and older. A prospective cohort study of 1183 patients suggests that patients with chronic kidney disease are at much greater risk of developing AMD compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/18\">",
"     18",
"    </a>",
"    ]. After multivariate adjustment, there was a three-fold higher risk for AMD among patients with an estimated glomerular filtration rate (GFR) less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 compared to those with GFRs &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (odds ratio of 3.2, 95% CI 1.8-5.7). The reason for this increased risk is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously unrecognized impairment of visual fields and retinal light sensitivity may be present among dialysis patients. In a study of one eye in each of 20 patients on hemodialysis compared with 20 eyes in 20 healthy patients, postdialysis mean deviation, a measure of visual field integrity, was significantly impaired, although intraocular pressure did not change [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive retinal injury may also be present in dialysis patients who profess normal vision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported that electroretinograms in patients with chronic renal failure were severely damaged, as evidenced by decreased b-amplitude of maximal combined response and delayed implicit time of oscillatory potentials [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, 10 of 20 dialysis patients undergoing hemodialysis evinced various abnormalities of the blink reflex, suggesting \"subclinical functional or anatomical impairment of the low brainstem reticular formation\" [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Expanded eye evaluation of prevalent hemodialysis patients is obviously needed to gain perspective on these preliminary findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SYSTEMIC DISORDERS ASSOCIATED WITH OCULORENAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of diseases are associated with both renal and ophthalmologic involvement. A survey of eye disorders associated with kidney disease is presented in the following sections. Detailed discussions of some of these disorders are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nephronopthisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent genetic cause of chronic renal failure in children is nephronophthisis. Multiple genes appear to underlie this disorder, with gene products that are linked to dysfunctional ciliary cells. When associated with retinitis pigmentosa, the renal-retinal disorder is termed the Senior-Loken syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperoxaluria (PHO) is a rare metabolic disorder with autosomal recessive inheritance; it is induced by one of two enzymatic defects, both of which result in markedly enhanced conversion of glyoxalate to poorly soluble oxalate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With type 1 (PH1) disease, there is a deficiency of the liver-specific intermediary metabolic enzyme alanine:glyoxalate aminotransferase [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With type 2 (PH2), there is a deficiency of the enzyme D-glycerate dehydrogenase which also has glyoxalate reductase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oxalate ions are excreted by the kidney where they can form an insoluble salt with calcium ions, thereby inducing urinary stones, and crystal deposition in the tubular lumen and renal parenchyma; this leads to nephrocalcinosis and renal failure. In one study of 14 patients with oxalosis, 10 developed renal failure, two of whom died without being offered dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/24\">",
"     24",
"    </a>",
"    ]. Although ocular fundus examination was normal in seven patients, five had numerous minute white round flecks at the posterior pole and near the retinal vessels (calcium oxalate crystals). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This flecked retinopathy, which is characterized by multiple yellowish-white lesions of various size and configuration (but without vascular or optic nerve abnormalities), can occur prior to or months to years after the onset of renal failure (",
"    <a class=\"graphic graphic_picture graphicRef50625 \" href=\"UTD.htm?12/43/12991\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/25\">",
"     25",
"    </a>",
"    ]. The finding of a flecked retinopathy is not specific, being reported in diverse disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alport syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome, which is X-linked (observed in almost all affected kindreds) or autosomal recessive (and extremely rarely autosomal dominant), induces renal failure and a high-frequency sensorineural deafness by the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A typical dot-and-fleck retinopathy occurs in approximately 85 percent of affected adult males, while anterior lenticonus is observed in 25 percent. Retinopathy and anterior lenticonus are detected in adolescence and worsen with time; retinal lesions are frequently present at the onset of renal failure, but anterior lenticonus producing distorted vision is detected later [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other ocular features include additional corneal dystrophies, microcornea, arcus, iris atrophy, cataracts, spontaneous lens rupture, spherophakia, posterior lenticonus, a poor macular reflex,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram hyperfluorescence, electrooculogram and electroretinogram abnormalities, and retinal pigmentation.",
"   </p>",
"   <p>",
"    Specific genetic testing may allow the identification of mutations of prognostic value in predicting both the age of onset of end-stage renal disease (ESRD) and the risk of eye problems in X-linked Alport syndrome (XLAS). A study of 681 male subjects from 179 families afflicted with XLAS found the average age of onset of ESRD was 37 years for those with missense mutations, 28 years for those with splice-site mutations, and 25 years for those with truncating mutations. Individuals with splice mutations or truncating mutations had twofold greater odds of developing eye problems compared to those with missense mutations. Refining the genotype-phenotype correlations may facilitate both evaluation and counseling of families afflicted with XLAS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autosomal recessive and X-linked Alport syndrome manifest identical ocular and other clinical features. However, retinopathy and cataracts are the only ocular abnormalities described in the exceedingly rare autosomal dominant form.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cystinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystinosis is a metabolic disease characterized by an accumulation of cystine in different organs and tissues, potentially leading to renal failure. Three forms of cystinosis have been described: the infantile (nephropathic) form, the intermediate (adolescent, late-onset) form; and the adult (benign) form.",
"   </p>",
"   <p>",
"    Extrarenal symptoms and findings among those with the nephropathic form are due to the intracellular accumulation of cystine in different tissues and organs. The eyes are involved early in the course of the disease, as cystine deposits in the cornea and the conjunctiva can be seen on slit-lamp examination. These deposits are responsible for photophobia, watering, and blepharospasm. Irregular and peripheral depigmentation of the retina is also an early finding. Visual impairment may occur in children older than 10 years.",
"   </p>",
"   <p>",
"    Several years following successful renal transplantation, children with nephropathic cystinosis may manifest progressively severe ocular complications, other than the deposition of corneal crystals. In a retrospective assessment of 172 patients at the National Institutes of Health between 1976 and 2000, eye complications in nephropathic cystinosis were noted with increasing prevalence as patients aged [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/30\">",
"     30",
"    </a>",
"    ]. These included superficial punctate keratopathy, filamentary keratopathy, severe peripheral corneal neovascularization, band keratopathy, and posterior synechiae with iris thickening and transillumination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the eye are common in patients with kidney transplantation. One study found that 42 of 80 renal allograft recipients developed ocular complications including [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posterior subcapsular cataract",
"     </li>",
"     <li>",
"      Opportunistic ocular infections",
"     </li>",
"     <li>",
"      Raised intraocular pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of chronic corticosteroids alone may induce multiple eye complications, particularly posterior cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a report of 176 renal transplant recipients, a posterior subcapsular cataract was present in 60 (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After excluding acute glaucoma, the presence of impaired vision and a painful red eye strongly suggests infection in recipients of solid organ transplants. Nocardial endophthalmitis, Cryptococcal choroiditis, cytomegalovirus chorioretinitis, and Listeria monocytogenes endophthalmitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BK virus-induced or polyomavirus-associated nephropathy (PVAN) due to the BK virus is an important cause of kidney transplant dysfunction and allograft loss. Treatment with low-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    may be complicated by anterior uveitis. In 14 kidney-transplant recipients given low dose cidofovir for PVAN, five (35 percent) patients developed anterior uveitis. Following discontinuance of cidofovir, there was complete resolution of uveitis in four patients treated with topical corticoids and cycloplegics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retinal fundus is a mirror of systemic arterial disease (",
"    <a class=\"graphic graphic_picture graphicRef66494 \" href=\"UTD.htm?25/51/26431\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=see_link\">",
"     \"Ocular effects of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fabry disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease is a rare X-linked recessive metabolic defect of alpha-galactosidase A. This results in the deposition of glycolipids (ceramide trihexoside) in the kidneys, eyes, and tonsils. Abnormal renal histology includes foamy vacuolation of glomerular visceral epithelial cells with widespread deposition of diagnostic myelin bodies (zebra bodies) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are relatively distinct abnormal findings upon examination of the eye. These include a dry eye with whorl-like corneal deposits, cream-colored capsular deposits, and faint posterior capsular opacity with a branching radial pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmic complications of diabetes mellitus are the most prevalent eye disorders (other than myopia) noted in dialysis patients. Appreciating that diabetes is the leading cause of blindness in adults, active collaboration with an ophthalmologist skilled in laser photocoagulation is vital to provide adequate care for such patients. In the United States, the retinal complications of diabetes necessitate laser therapy in 75 percent of ESRD diabetic patients with end-stage renal disease (ESRD) by the time dialysis is initiated. In addition, further laser therapy and regular screening for glaucoma are part of routine care for diabetic dialysis patients. The correlation between diabetic retinopathy and diabetic nephropathy is so strong (nearly 100 percent coincidence) that diabetes should be doubted as the cause of renal insufficiency in any patient with a normal retinal exam that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography.",
"   </p>",
"   <p>",
"    Although few studies have addressed the point directly, heparinization during hemodialysis does not increase the risk of hemorrhagic complications due to diabetic retinopathy. One approach to assessing the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced risk of retinal hemorrhage is to compare the course of diabetic eye disease in individuals treated with peritoneal dialysis versus those undergoing hemodialysis. A prospective, uncontrolled study that evaluated visual changes in 112 diabetic patients, of whom 63 and 37 percent were treated with hemodialysis and peritoneal dialysis, respectively, found that the loss of vision was independent of the dialysis modality, glucose control, and type of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/41\">",
"     41",
"    </a>",
"    ]. Provided that hypertension is effectively managed (see below), there does not appear to be an undue hazard imposed by heparin anticoagulation during hemodialysis to diabetic patients with retinopathy.",
"   </p>",
"   <p>",
"    Hypertension, which is also present in the majority of dialysis patients, accelerates progression of diabetic retinopathy, and may, by itself, cause retinal and vitreous hemorrhage. A detailed discussion concerning the manifestations and treatment of diabetic retinopathy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Deferoxamine toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal injury can be caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    treatment for aluminum intoxication (resulting in bone disease or dialysis dementia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/42\">",
"     42",
"    </a>",
"    ]. Deferoxamine has minimal toxicity, probably due to its low lipid solubility. In dialysis patients, however, deferoxamine toxicity is dose related; high doses may cause visual disturbance that is characterized by decreased acuity, diminished night vision, and loss of color vision.",
"   </p>",
"   <p>",
"    Fundoscopic changes have been observed even in asymptomatic patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ; they included swelling of the optic disc, depigmentation of the macular area, and hypo- or hyperpigmentation (pigmentary stippling) throughout the fundus. In dialysis patients receiving deferoxamine to extract aluminum from bone, retinal toxicity may occur with relatively low dosages. Therefore, careful, repeated ophthalmologic examinations should be scheduled for dialysis patients begun on a course of deferoxamine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narrow or wide angle glaucoma is not observed at a higher incidence among patients with ESRD. The relationship of CKD to glaucoma was assessed in 3280 Malay adults aged 40 to 79 years using ocular examination and applanation tonometry to measure intraocular pressure. The prevalence of chronic kidney disease (CKD) (defined as estimated GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 or the presence of",
"    <span class=\"nowrap\">",
"     micro/macroalbuminuria)",
"    </span>",
"    was 27.9 and glaucoma 4.5 percent. Intraocular pressure was higher in individuals with CKD compared with those without CKD (15.8 versus 15.3 mmHg, respectively); however no association between CKD and glaucoma was noted.",
"   </p>",
"   <p>",
"    Intraocular pressure is also not significantly altered during standard or high flux hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Measurement of the intraocular pressure before, during, and after hemodialysis reveals a slight but nonsignificant rise when assessed after completion of dialysis. In usual practice, this variation in intraocular pressure during dialytic therapy is without clinical consequence.",
"   </p>",
"   <p>",
"    However, there may be a significant decrease in intraocular pressure among those who undergo prolonged ultrafiltration. A single case report documented a decrease in intraocular pressure of 53 to 14 mmHg during a hemodialysis session in which the weight loss was 5.7 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/46\">",
"     46",
"    </a>",
"    ]. Plasma osmolarity was almost constant during the procedure (beginning and ending pressures of 295 and 305",
"    <span class=\"nowrap\">",
"     mosm/L,",
"    </span>",
"    respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of systemic diseases resulting from immunologic pathogenic mechanisms are associated with oculorenal manifestations.",
"   </p>",
"   <p>",
"    The major ocular manifestations of autoimmune disorders of the eye include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant cell arteritis; transient or permanent partial or complete loss of vision.",
"     </li>",
"     <li>",
"      Takayasu's arteritis; transient visual loss",
"     </li>",
"     <li>",
"      Polyarteritis nodosa; a wide variety of visual disturbances, including choroidal vasculitis",
"     </li>",
"     <li>",
"      Kawasaki disease; bilateral nonexudative conjunctivitis (greater than 90 percent), photophobia, and anterior uveitis",
"     </li>",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA, and microscopic polyarteritis; orbital involvement with proptosis (due to orbital pseudotumor) and conjunctivitis. Leukocytoclastic vasculitis and focal microhemorrhages in the lacrimal sac wall presenting as a unilateral orbital mass in disseminated GPA can be \"cured\" by dacryocystorhinostomy (excision of the mass) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8456/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura; scleritis and anterior uveitis",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome; rarely blindness, due to infarcts",
"     </li>",
"     <li>",
"      Churg-Strauss syndrome; eyelid and conjunctival granulomas, scleritis, and others",
"     </li>",
"     <li>",
"      Behcet's disease; bilateral and episodic anterior uveitis",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus; numerous manifestations and disorders, such as keratoconjunctivitis sicca, retinal vasculitis, episcleritis, scleritis",
"     </li>",
"     <li>",
"      Primary antiphospholipid syndrome; blurred vision (red eye) with pain",
"     </li>",
"     <li>",
"      Sarcoidosis; typically granulomatous uveitis, anterior uveitis, and retinal periphlebitis",
"     </li>",
"     <li>",
"      Sj&ouml;grens syndrome; keratoconjunctivitis sicca",
"     </li>",
"     <li>",
"      Tubulointerstitial nephritis and uveitis (TINU) syndrome; uveitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed discussions of the clinical manifestations of these disorders are presented in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7518077\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye findings associated with end-stage renal disease include conjunctival erythema, metastatic calcification, age-related macular degeneration (AMD) and cataracts. Uremia may rarely be associated with transient cortical blindness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ophthalmoscopic evaluation and general findings in chronic kidney disease and end-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large number of diseases are associated with both renal and ophthalmologic involvement. These include diabetes, hypertension, autoimmune disorders, nephronophthisis, primary hyperoxaluria, Alport syndrome, and cystinosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Systemic disorders associated with oculorenal findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities of the eye are common in patients with kidney transplantation and include posterior subcapsular cataract, opportunistic ocular infections, and raised intraocular pressure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Kidney transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Narrow or wide angle glaucoma is not observed at a higher incidence among patients with ESRD. Intraocular pressure is also not significantly altered during standard or high flux hemodialysis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glaucoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/1\">",
"      Grunwald JE, Alexander J, Maguire M, et al. Prevalence of ocular fundus pathology in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/2\">",
"      Hsiao CH, Chao A, Chu SY, et al. Association of severity of conjunctival and corneal calcification with all-cause 1-year mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/3\">",
"      Tyler HR. Neurologic disorders seen in the uremic patient. Arch Intern Med 1970; 126:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/4\">",
"      Jarosz JM, Howlett DC, Cox TC, Bingham JB. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology 1997; 39:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/5\">",
"      Merimsky O, Nisipeanu P, Loewenstein A, et al. Interferon-related cortical blindness. Cancer Chemother Pharmacol 1992; 29:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/6\">",
"      Berlyne GM, Shaw AB. Red eyes in renal failure. Lancet 1967; 1:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/7\">",
"      Gofman L, S&uuml;le T, Agoston I. Red eyes in renal disease. Acta Med Acad Sci Hung 1973; 30:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/8\">",
"      Klaassen-Broekema N, van Bijsterveld OP. Diffuse and focal hyperaemia of the outer eye in patients with chronic renal failure. Int Ophthalmol 1993; 17:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/9\">",
"      Tokuyama T, Ikeda T, Sato K, et al. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients. Am J Kidney Dis 2002; 39:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/10\">",
"      Cohen SL, Gorchein A, Hayward JA, et al. Pingueculae--an association with renal failure. Q J Med 1974; 43:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/11\">",
"      Jaros PA, DeLuise VP. Pingueculae and pterygia. Surv Ophthalmol 1988; 33:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/12\">",
"      Nakaishi H, Yamamoto M, Ishida M, et al. Pingueculae and pterygia in motorcycle policemen. Ind Health 1997; 35:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/13\">",
"      Chugh SK, Goel A. Bilateral cataracts as the presenting manifestation of chronic renal failure. J Assoc Physicians India 1992; 40:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/14\">",
"      Straub W, Freund J. [Cataract after extracorporal dialysis therapy]. Klin Monbl Augenheilkd 1970; 157:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/15\">",
"      Laqua H. [Cataract in chronic renal insufficiency and dialysis]. Klin Monbl Augenheilkd 1972; 160:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/16\">",
"      Koch HR, Siedek M, Weikenmeier P, Metzler U. [Cataract during intermittent hemodialysis. The influence of hypocalcemia on the development of opacities (author's transl)]. Klin Monbl Augenheilkd 1976; 168:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Prevalence of visual impairment and selected eye diseases among persons aged &gt;/=50 years with and without diabetes--United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/18\">",
"      Liew G, Mitchell P, Wong TY, et al. CKD increases the risk of age-related macular degeneration. J Am Soc Nephrol 2008; 19:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/19\">",
"      Pelit A, Z&uuml;mr&uuml;tdal A, Akova Y. The effect of hemodialysis on visual field test in patients with chronic renal failure. Curr Eye Res 2003; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/20\">",
"      Lim JH, Kim IT. The electroretinogram in chronic renal failure. Korean J Ophthalmol 1998; 12:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/21\">",
"      Resende LA, Caramori JC, Kimaid PA, Barretti P. Blink reflex in end-stage-renal disease patients undergoing hemodialysis. J Electromyogr Kinesiol 2002; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/22\">",
"      Danpure CJ. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1. J Nephrol 1998; 11 Suppl 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/23\">",
"      Giafi CF, Rumsby G. Primary hyperoxaluria type 2: enzymology. J Nephrol 1998; 11 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/24\">",
"      Lasram L, Kammoun A, Karray T, et al. [Ocular signs of primary hyperoxaluria type I]. J Fr Ophtalmol 1997; 20:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/25\">",
"      De Laey JJ. Flecked retina disorders. Bull Soc Belge Ophtalmol 1993; 249:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/26\">",
"      Espaillat A, Aiello LP, Arrigg PG, et al. Canthaxanthine retinopathy. Arch Ophthalmol 1999; 117:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/27\">",
"      Flinter F. Alport's syndrome. J Med Genet 1997; 34:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/28\">",
"      Rhys C, Snyers B, Pirson Y. Recurrent corneal erosion associated with Alport's syndrome. Rapid communication. Kidney Int 1997; 52:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/29\">",
"      Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/30\">",
"      Tsilou ET, Rubin BI, Reed GF, et al. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea 2002; 21:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/31\">",
"      Das T, Gupta A, Sakhuja V, et al. Ocular complications in renal allograft recipients. Nephrol Dial Transplant 1991; 6:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/32\">",
"      Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/33\">",
"      Matsunami C, Hilton AF, Dyer JA, et al. Ocular complications in renal transplant patients. Aust N Z J Ophthalmol 1994; 22:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/34\">",
"      Suppiah R, Abraham G, Sekhar U, et al. Nocardial endophthalmitis leading to blindness in a renal transplant recipient. Nephrol Dial Transplant 1999; 14:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/35\">",
"      Biswas J, Gopal L, Sharma T, et al. Recurrent cryptococcal choroiditis in a renal transplant patient: clinicopathologic study. Retina 1998; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/36\">",
"      Ba��&ccedil;il N, Erdem Y, Yal&ccedil;in AU, et al. Evisceration of the eye in a renal transplant recipient with cytomegalovirus chorioretinitis. Am J Nephrol 1996; 16:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/37\">",
"      Algan M, Jonon B, George JL, et al. Listeria monocytogenes endophthalmitis in a renal-transplant patient receiving ciclosporin. Ophthalmologica 1990; 201:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/38\">",
"      Lopez V, Sola E, Gutierrez C, et al. Anterior uveitis associated with treatment with intravenous cidofovir in kidney transplant patients with BK virus nephropathy. Transplant Proc 2006; 38:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/39\">",
"      Ohkubo H. Several functional and fluorescein fundus angiographic findings in Fabry's disease. Ophthalmologica 1988; 196:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/40\">",
"      Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979; 97:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/41\">",
"      Diaz-Buxo JA, Burgess WP, Greenman M, et al. Visual function in diabetic patients undergoing dialysis: comparison of peritoneal and hemodialysis. Int J Artif Organs 1984; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/42\">",
"      Porter JB, Huehns ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989; 2:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/43\">",
"      Ravelli M, Scaroni P, Mombelloni S, et al. Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol Dial Transplant 1990; 5:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/44\">",
"      Hojs R, Pahor D. Intraocular pressure in chronic renal failure patients treated with maintenance hemodialysis. Ophthalmologica 1997; 211:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/45\">",
"      Austin JN, Klein M, Mishell J, et al. Intraocular pressures during high-flux hemodialysis. Ren Fail 1990; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/46\">",
"      Tokuyama T, Ikeda T, Ishikawa H, Sato K. Marked decrease in intraocular pressure in a neovascular glaucoma patient during hemodialysis. Jpn J Ophthalmol 1997; 41:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/47\">",
"      Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 2007; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/48\">",
"      Bennett B, Booth T, Quan A. Late onset seizures, hemiparesis and blindness in hemolytic uremic syndrome. Clin Nephrol 2003; 59:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/49\">",
"      Izzedine H, Bodaghi B, Launay-Vacher V, Deray G. Oculorenal manifestations in systemic autoimmune diseases. Am J Kidney Dis 2004; 43:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8456/abstract/50\">",
"      Ghanem RC, Chang N, Aoki L, et al. Vasculitis of the lacrimal sac wall in Wegener granulomatosis. Ophthal Plast Reconstr Surg 2004; 20:254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1912 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8456=[""].join("\n");
var outline_f8_16_8456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7518077\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OPHTHALMOSCOPIC EVALUATION AND GENERAL FINDINGS IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Red eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pingueculae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cataracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SYSTEMIC DISORDERS ASSOCIATED WITH OCULORENAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nephronopthisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alport syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Deferoxamine toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7518077\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1912|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/43/12991\" title=\"picture 1\">",
"      Flecked retina Stargardts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/51/26431\" title=\"picture 2\">",
"      Grade III HPT retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=related_link\">",
"      Ocular effects of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8457="Treatment and prevention of Shigella infections in children";
var content_f8_16_8457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Shigella infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Shai Ashkenazi, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8457/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/16/8457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Shigella",
"    </em>",
"    infections are a major cause of pediatric morbidity and mortality. Worldwide, about 165 million cases occur annually with 1 million associated deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 70 percent of episodes and 60 percent of deaths involve children younger than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, the incidence of",
"    <em>",
"     Shigella",
"    </em>",
"    infections is 4 to 8 per 100,000, with more than 13,300 reported cases in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/2\">",
"     2",
"    </a>",
"    ]. The mortality in developed countries is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Shigella",
"    </em>",
"    infection is characterized by high fever, abdominal cramps, and diarrhea; extraintestinal manifestations also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/4\">",
"     4",
"    </a>",
"    ]. The characteristic small-volume,",
"    <span class=\"nowrap\">",
"     bloody/mucous",
"    </span>",
"    stools are present in approximately one-half of the children with shigellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/4\">",
"     4",
"    </a>",
"    ]. Neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/5\">",
"     5",
"    </a>",
"    ] and children with underlying immune deficiency (including HIV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] or malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] are at increased risk of bacteremia and other complications of shigellosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of",
"    <em>",
"     Shigella",
"    </em>",
"    gastroenteritis should be considered on the basis of epidemiology (confirmed cases in the family or day care center) or in a child who appears toxic and has a sudden onset of high fever, bloody diarrhea, abdominal cramping, tenesmus, and polymorphonuclear leukocytes on a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"     methylene blue",
"    </a>",
"    stain of the stool, when such a stain is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of and prevention of",
"    <em>",
"     Shigella",
"    </em>",
"    infection will be reviewed here. The microbiology, epidemiology, pathogenesis, clinical manifestations, and diagnosis are discussed separately, as is the treatment of",
"    <em>",
"     Shigella",
"    </em>",
"    in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link\">",
"     \"Treatment and prevention of Shigella infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of the treatment of acute gastroenteritis in children, irrespective of the cause, which usually is not known at the time of presentation, is correction of fluid and electrolyte losses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/4\">",
"     4",
"    </a>",
"    ]. Oral rehydration is preferred when feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/10\">",
"     10",
"    </a>",
"    ], but intravenous fluids may be necessary. Fluid repletion in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of intestinal antimotility drugs, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=see_link\">",
"     diphenoxylate",
"    </a>",
"    (Lomotil&reg;), should be avoided in children with suspected shigellosis. These drugs may prolong the duration of fever, diarrhea, and excretion of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early restoration of oral intake, especially protein, is important, particularly in developing countries, to prevent malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In addition, the administration of vitamin A or zinc, or the ingestion of unripe, mature green banana fruit, may hasten resolution of symptoms in malnourished children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/15-19\">",
"     15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe toxemia or suspected bacteremia, underlying immune deficiency, and who are unable to take oral medications should be hospitalized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing antimicrobial resistance of",
"    <em>",
"     Shigella",
"    </em>",
"    species is a major problem in the treatment of shigellosis. Antibiotic susceptibility testing is essential for management of all patients with suspected",
"    <em>",
"     Shigella",
"    </em>",
"    infection.",
"   </p>",
"   <p>",
"    High rates of antimicrobial resistance were first reported in Asia, Africa, and South America, but antimicrobial resistance has rapidly spread to developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In India and Bangladesh, 20 percent or more of isolates are resistant to nalidixic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Resistance to nalidixic acid has also been reported in England [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/26\">",
"     26",
"    </a>",
"    ] and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/22\">",
"     22",
"    </a>",
"    ]. Increasing levels of resistance to ceftriaxone and azithromycin have been reported in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] and France [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/29\">",
"     29",
"    </a>",
"    ]. Ceftriaxone and ciprofloxacin-resistant",
"    <em>",
"     Shigella",
"    </em>",
"    strains have been reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Some, but not all, of these cases were associated with international travel or adoption.",
"   </p>",
"   <p>",
"    Antimicrobial resistance is an increasing problem in the United States. Since 1999, the National Antimicrobial Resistance Monitoring System for Enteric Bacteria has tested every 10",
"    <sup>",
"     th",
"    </sup>",
"    (through 2002), or 20",
"    <sup>",
"     th",
"    </sup>",
"    (2003-2010)",
"    <em>",
"     Shigella",
"    </em>",
"    isolate from 16 public health laboratories across the United States for antimicrobial susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/33\">",
"     33",
"    </a>",
"    ]. Among the 407 isolates tested during 2010, the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/34\">",
"     34",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef73405 \" href=\"UTD.htm?29/5/29790\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most isolates were susceptible to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (only one isolate was resistant) and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (98 percent).",
"     </li>",
"     <li>",
"      Forty-one percent of isolates were resistant to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      , 48 percent to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX), and 4 percent to nalidixic acid.",
"     </li>",
"     <li>",
"      Forty percent of isolates were resistant to &ge;3 antimicrobial classes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In outbreaks of",
"    <em>",
"     S. sonnei",
"    </em>",
"    associated with day care centers reported to the Centers for Disease Control and Prevention in 2005, up to 89 percent of isolates were resistant to both",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major route for dissemination of multiple resistance is by horizontal transfer of plasmids carrying antibiotic resistance (R-plasmids). A commonly isolated plasmid carries resistance against",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    , sulfonamides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"     trimethoprim",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/36\">",
"     36",
"    </a>",
"    ]. Ampicillin resistance also is mediated by beta-lactamases, most frequently OXA-1 and TEM-1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of antibiotic therapy for",
"    <em>",
"     Shigella",
"    </em>",
"    include improvement in symptoms and decreased spread of infection to contacts. In randomized controlled trials, appropriate antimicrobial treatment of",
"    <em>",
"     Shigella",
"    </em>",
"    gastroenteritis reduces the duration of fever, diarrhea, and fecal excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. It also may reduce the risk of developing complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized, placebo-controlled trials during the 1960s and early 1970s (before the widespread development of resistance to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    ), children with",
"    <em>",
"     Shigella",
"    </em>",
"    infection who were treated with ampicillin had decreased duration of diarrhea, fever, and fecal shedding than those who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The findings of the largest two studies are presented below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 52 children hospitalized with",
"      <em>",
"       Shigella",
"      </em>",
"      gastroenteritis, compared with those who received placebo, those who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      had shorter duration of diarrhea (3.3 versus 6 days), fever (1.3 versus 2.6 days), and fecal shedding (positive stool culture for two versus five days) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized study of 373 children with acute diarrhea who were treated as outpatients, 101 children had stool cultures positive for",
"      <em>",
"       Shigella",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/38\">",
"       38",
"      </a>",
"      ]. Compared with those who received placebo, fewer children with",
"      <em>",
"       Shigella",
"      </em>",
"      who were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      had positive stool cultures after 48 hours (8 versus 70 percent), and fewer continued to have diarrhea after five days (5 versus 50 percent). None of the patients who were treated with ampicillin required hospital admission or treatment with another antibiotic after completion of therapy (compared with one and five children in the placebo group, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decreased duration of shedding with antimicrobial therapy reduces the risk of person-to-person spread of the infection. In the absence of specific antibiotic treatment, children with",
"    <em>",
"     Shigella",
"    </em>",
"    gastroenteritis shed the organism for up to four weeks, and children with immune deficiency for much longer periods, even if their symptoms have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     Shigella",
"    </em>",
"    is highly contagious; ingestion of only 10 to 100 organisms can produce disease. Therefore, treatment of an infected child at risk to transmit the disease to others (eg, a day care attendee, hospitalized patient) is particularly compelling.",
"   </p>",
"   <p>",
"    The benefits of antimicrobial therapy discussed above outweigh the potential risks of therapy, which include the possibility of favoring emergence of resistant organisms, and potential adverse effects.",
"    <em>",
"     Shigella dysenteriae",
"    </em>",
"    serotype 1, which is rare in developed countries, can produce Shiga toxin and may be complicated with hemolytic-uremic syndrome (HUS). Antimicrobial therapy does not seem to increase the risk of",
"    <em>",
"     S. dysenteriae",
"    </em>",
"    -related HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Hemolytic-uremic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding initiation of antimicrobial therapy must consider the appearance of the patient, the presence of host factors that predispose to more severe infection, and public health considerations.",
"   </p>",
"   <p>",
"    We recommend",
"    <strong>",
"     empiric",
"    </strong>",
"    antimicrobial therapy for shigellosis in children and adolescents who present with suspected shigellosis",
"    <span class=\"nowrap\">",
"     (bloody/mucous",
"    </span>",
"    diarrhea, high fever) and are immunocompromised or bacteremic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend antimicrobial therapy for children and adolescents with culture-proven",
"    <em>",
"     Shigella",
"    </em>",
"    who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have bacteremia",
"     </li>",
"     <li>",
"      Require hospitalization",
"     </li>",
"     <li>",
"      Attend day care",
"     </li>",
"     <li>",
"      Live in institutions",
"     </li>",
"     <li>",
"      Are involved in food handling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest antimicrobial therapy for",
"    <strong>",
"     symptomatic",
"    </strong>",
"    children and adolescents who do not fall into one of the above categories and have one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Culture-proven shigellosis",
"     </li>",
"     <li>",
"      Suspected shigellosis according to epidemiologic data (eg, outbreak setting, positive culture in household or day care contact, etc)",
"     </li>",
"     <li>",
"      Suspected shigellosis on clinical basis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of mild cases or of children who have recovered by the time the report of positive",
"    <em>",
"     Shigella",
"    </em>",
"    culture is available is controversial. Antimicrobial treatment of such children is unlikely to significantly affect the clinical course but will shorten fecal excretion and thus reduce the spread of this highly contagious bacterium. We suggest that such children who are in hospitals, day care centers, or institutions be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medication regimen is determined by severity of illness, local resistance patterns, and history of travel to an area of frequent resistance. Most authorities suggest that antibiotics be started when shigellosis is suspected clinically, before culture confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/46\">",
"     46",
"    </a>",
"    ]. However, because of changing patterns of antibiotic resistance, susceptibility testing should be performed on all isolates, and empiric therapy changed as necessary based upon the results [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/29,46\">",
"     29,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the agents recommended below are not yet approved by the United States Food and Drug Administration (FDA) for the treatment of shigellosis in children. However, with increasing resistance of shigellae to the approved agents, it is sometimes necessary to treat with an agent that is not yet approved, particularly if it is the only agent to which the isolate is sensitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral antibiotic therapy is indicated for children with proven or suspected shigellosis in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient unable to take oral medications (vomiting, stupor, etc)",
"     </li>",
"     <li>",
"      Patient with underlying immune deficiency; shigellosis in children with immune deficiency, including acquired immunodeficiency syndrome, is associated with a prolonged course and increased risk of complications, suggesting the need for parenteral therapy.",
"     </li>",
"     <li>",
"      Severe toxemia or suspected bacteremia; bacteremia is associated with increased mortality. In one study, signs that correlated with bacteremia included leukocytosis, hypothermia, temperature &gt;39&ordm;C, and lethargy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Systemic complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended first-line parenteral therapy for children with suspected shigellosis when the antibiotic susceptibility of the organism is unknown is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [maximum 1.5 g] in a single daily dose, for five days). Patients with no underlying immune deficiency or bacteremia who are afebrile after two days may be treated with two doses only [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/47\">",
"     47",
"    </a>",
"    ]. Changes to this empiric regimen can be made when culture results are available, or if the patient remains symptomatic on or after three days of therapy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a prospective, open study, 40 children (mean age 4.5 years) with severe",
"    <em>",
"     Shigella",
"    </em>",
"    dysentery were randomly assigned to intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for one to two days followed by intramuscular or oral therapy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/48\">",
"     48",
"    </a>",
"    ]. All of the",
"    <em>",
"     Shigella",
"    </em>",
"    isolates were sensitive to ceftriaxone, whereas 28 percent were resistant to ampicillin. Children treated with ceftriaxone had shorter mean duration of diarrhea (2.5 versus 6.8 days), greater rates of eradication from the stool after five days (100 versus 60 percent) and fewer bacteriologic relapses (0 versus 40 percent) than those treated with ampicillin. In comparative studies, two days of ceftriaxone therapy was as effective as five days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. However, a single dose of ceftriaxone did not eradicate",
"    <em>",
"     Shigella",
"    </em>",
"    from the stool in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [maximum 500",
"    <span class=\"nowrap\">",
"     mg/dose]",
"    </span>",
"    every 12 hours for 5 days) is an alternative therapy for children older than 17 years and those with contraindications to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/46,50,51\">",
"     46,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral treatment of shigellosis depends upon local resistance patterns.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      &ndash; Because of high resistance to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"       trimethoprim",
"      </a>",
"      -sulfamethoxazole (TMP-SMX) and ampicillin worldwide, these agents are suggested",
"      <strong>",
"       only if the isolated strain is susceptible",
"      </strong>",
"      , or if current local microbiologic data suggest susceptibility.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      is less effective than ampicillin because of its rapid absorption from the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/45\">",
"       45",
"      </a>",
"      ]. When indicated, the suggested doses for TMP-SMX and ampicillin are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TMP-SMX : 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      TMP and 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      SMX per day (maximum 160 mg TMP and 600 mg SMX), in two divided doses for five days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      : 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in four divided doses for five days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      &ndash; In areas with high resistance to TMP-SMX and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      , azithromycin is the suggested first-line oral treatment for shigellosis in children younger than 18 years of age when the antibiotic susceptibility of the organism is unknown. However, resistance to azithromycin is increasing, and susceptibility testing should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      : 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the first day (maximum 500 mg) and then 6",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"      (maximum 250 mg) for an additional four days",
"      <br/>",
"      <br/>",
"      In a double-blind randomized trial, azithromycin was found efficacious in adults with shigellosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/52\">",
"       52",
"      </a>",
"      ]. In addition, in an open controlled study of 75 children with culture-proven shigellosis in Paraguay, azithromycin and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"       cefixime",
"      </a>",
"      had a similar clinical efficacy, but azithromycin had a better bacteriologic efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/53\">",
"       53",
"      </a>",
"      ]. Azithromycin was clinically and microbiologically superior to nalidixic acid in an outbreak of shigellosis in children in Israel [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative treatments for children younger than 18 years of age include nalidixic acid and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"     cefixime",
"    </a>",
"    as discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quinolones &ndash; Oral fluoroquinolones are the recommended first-line treatment for shigellosis in children older than 17 and in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link\">",
"       \"Treatment and prevention of Shigella infection in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      , although highly effective, are not used in younger children when the organism is likely to be susceptible to another agent because of concern about damage to cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/55\">",
"       55",
"      </a>",
"      ]. However, the use of oral quinolones may be necessary in children with severe disease caused by resistant strains and no other feasible alternative [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/45,55\">",
"       45,55",
"      </a>",
"      ]. Experience with ciprofloxacin in children is extensive [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/56\">",
"       56",
"      </a>",
"      ]. It is approved by the United States FDA for the treatment of complicated urinary tract infections in children and has been used to treat children with acute invasive diarrhea without the subsequent development of joint problems [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/51,57\">",
"       51,57",
"      </a>",
"      ]. The doses are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      : 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, maximum 1 g per day in two divided doses for five days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       Norfloxacin",
"      </a>",
"      : 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for five days",
"      <br/>",
"      <br/>",
"      In developed countries, where resistance is low, nalidixic acid is an alternative to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      therapy for children younger than 18 years of age when the antibiotic susceptibility of the organism is unknown.",
"     </li>",
"     <li>",
"      Nalidixic acid (55",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in four divided doses) for five days",
"      <br/>",
"      <br/>",
"      However, in studies in children and adults, nalidixic acid was inferior to fluoroquinolones and azithromycin in reducing duration of diarrhea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eradication of the organism from the stool [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/54,58-60\">",
"       54,58-60",
"      </a>",
"      ]. In the study comparing nalidixic acid and norfloxacin in children, none of the children treated with norfloxacin developed joint problems at four months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cephalosporins &ndash; First- and second-generation cephalosporins are ineffective against shigellosis; the main limitation is delayed fecal eradication of the pathogen [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/4\">",
"       4",
"      </a>",
"      ]. Parenteral third-generation cephalosporins are effective in children. Oral third-generation cephalosporins, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"       cefixime",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"       ceftibuten",
"      </a>",
"      , appear to be effective, as well [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Parenteral therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Cefixime may be used as an alternative to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      therapy for children younger than 18 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"       Cefixime",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      in a single dose, maximum 400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for five days; a shorter course of therapy (two days) was associated with bacteriologic failures [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one controlled trial, 77 children in Israel with culture-proven shigellosis were randomly assigned to treatment with cefixime (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or TMP-SMX (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day TMP and 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day TMP-SMX) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/61\">",
"       61",
"      </a>",
"      ]. In the cefixime group, all isolates were susceptible; in the TMP-SMX group, 32 isolates were resistant and 7 susceptible. Compared with those in the TMP-SMX group, more patients treated with cefixime had clinical cure by day five (89 percent versus 24 percent) and bacteriologic cure by day three (78 versus 23 percent). The response to treatment was similar in the cefixime- and TMP-SMX-susceptible groups.",
"      <br/>",
"      <br/>",
"      In another study in Japan, oral cefixime was more effective than oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/62\">",
"       62",
"      </a>",
"      ]. In a separate study,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"       ceftibuten",
"      </a>",
"      was as effective as TMP-SMX [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In contrast, oral cefixime does not appear to be effective in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/65\">",
"       65",
"      </a>",
"      ]. The observed difference in response to cephalosporins may be related to differences in the populations. In the pediatric study, described above, the predominant isolate was",
"      <em>",
"       S. sonnei",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/61\">",
"       61",
"      </a>",
"      ], whereas in the adult population, the predominant isolates were",
"      <em>",
"       S. dysenteriae",
"      </em>",
"      and",
"      <em>",
"       S. flexneri",
"      </em>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement is expected within one to two days if",
"    <em>",
"     Shigella",
"    </em>",
"    infection is treated with an antibiotic to which the isolate is susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/66\">",
"     66",
"    </a>",
"    ]. A resistant organism should be suspected, and antimicrobial therapy changed accordingly, in patients with persistent fever, grossly bloody stools, or unchanged stool frequency by day three of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/66\">",
"     66",
"    </a>",
"    ]. Morbidity and mortality are increased in patients in whom the isolate is not susceptible to the initial antimicrobial agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTROL MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control measures to prevent spread are an important component of the management of shigellosis. General recommendations include the use of safe drinking water, chlorination of unreliable water sources, strict hand washing, and refrigeration and proper cooking of food. A meta-analysis suggested that hand washing with soap reduces the risk of shigellosis by 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Food handlers infected with",
"    <em>",
"     Shigella",
"    </em>",
"    must be treated with antibiotics and should not be involved in the preparation of food until their stool cultures are negative, which generally requires at least 48 hours of antibiotic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to standard precautions, contact precautions are indicated for the duration of illness with or hospitalization for",
"    <em>",
"     Shigella",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     School or day care",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <em>",
"     Shigella",
"    </em>",
"    infection occurs in a child attending day care or in a staff member, stool cultures should be obtained from other symptomatic day care attendees, staff members, and household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/45\">",
"     45",
"    </a>",
"    ]. The local health department should be contacted to assess and manage potential outbreaks. Symptomatic persons with positive stool cultures should be excluded from the child care center until appropriate antibiotic therapy is initiated and &ge;24 hours after diarrhea has resolved and, depending upon local regulations, stool cultures are negative for",
"    <em>",
"     Shigella",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Additional control measures include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8457/abstract/35,70,71\">",
"     35,70,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appropriate hand washing and diapering practices",
"     </li>",
"     <li>",
"      Scheduling hand washing sessions on arrival at the day care center, before meals, or after playing outdoors",
"     </li>",
"     <li>",
"      Supervised hand washing for young children",
"     </li>",
"     <li>",
"      Eliminating water play areas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vaccine against shigellosis is not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    (which is not absorbed), to prevent traveler's diarrhea is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link&amp;anchor=H26#H26\">",
"     \"Travelers' diarrhea\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correction of fluid and electrolyte losses is the mainstay of treatment for acute gastroenteritis in children, irrespective of the cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"       \"Oral rehydration therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend not using antimotility drugs in children with suspected shigellosis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increasing antimicrobial resistance of",
"      <em>",
"       Shigella",
"      </em>",
"      species is a major problem in treating shigellosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of antibiotic therapy for",
"      <em>",
"       Shigella",
"      </em>",
"      include improvement in symptoms and decreased spread of infection to contacts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decisions regarding initiation of antimicrobial therapy must consider the appearance of the patient, the presence of host factors that predispose to more severe infection, and public health considerations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       empiric",
"      </strong>",
"      antimicrobial therapy for shigellosis in children and adolescents who present with suspected shigellosis",
"      <span class=\"nowrap\">",
"       (bloody/mucous",
"      </span>",
"      diarrhea, high fever) and are immunocompromised or bacteremic (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antimicrobial therapy for children and adolescents with culture-proven",
"      <em>",
"       Shigella",
"      </em>",
"      who have bacteremia, require hospitalization, attend day care, live in institutions, or are involved in food handling (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antimicrobial therapy for symptomatic children and adolescents with culture-proven shigellosis or suspected shigellosis according to epidemiologic data or clinical presentation (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The empiric antimicrobial regimen is determined by the severity of illness, local resistance patterns, and history of travel to an area of frequent resistance. Susceptibility testing should be performed on all isolates. Empiric therapy should be altered as necessary when results of susceptibility tests are available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral antimicrobial therapy is indicated for children with proven or suspected shigellosis and one or more of the following: severe toxemia or bacteremia, underlying immune deficiency, inability to take oral medications. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Parenteral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral treatment of shigellosis depends upon local resistance patterns. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic persons with stool cultures positive for",
"      <em>",
"       Shigella",
"      </em>",
"      should be excluded from day care until treatment is initiated, the diarrhea has resolved, and stool cultures are negative for",
"      <em>",
"       Shigella",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'School or day care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/1\">",
"      Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/2\">",
"      Notice to readers: Final 2011 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2012; 61:624.",
"     </a>",
"    </li>",
"    <li>",
"     Ashkenazi S, Cleary TG. Shigella species. In: Principles and practice of pediatric infectious diseases, 3rd, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, Philadelphia 2008. p.817.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/4\">",
"      Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis 2004; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/5\">",
"      Viner Y, Miron D, Gottfried E, et al. Neonatal shigellosis. Isr Med Assoc J 2001; 3:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/6\">",
"      Baer JT, Vugia DJ, Reingold AL, et al. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999; 5:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/7\">",
"      Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/8\">",
"      Struelens MJ, Patte D, Kabir I, et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 1985; 152:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/9\">",
"      Greenberg D, Marcu S, Melamed R, Lifshitz M. Shigella bacteremia: a retrospective study. Clin Pediatr (Phila) 2003; 42:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/10\">",
"      Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 2008; 46 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/11\">",
"      DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/12\">",
"      Kabir I, Butler T, Underwood LE, Rahman MM. Effects of a protein-rich diet during convalescence from shigellosis on catch-up growth, serum proteins, and insulin-like growth factor-I. Pediatr Res 1992; 32:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/13\">",
"      Kabir I, Rahman MM, Haider R, et al. Increased height gain of children fed a high-protein diet during convalescence from shigellosis: a six-month follow-Up study. J Nutr 1998; 128:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/14\">",
"      Mazumder RN, Hoque SS, Ashraf H, et al. Early feeding of an energy dense diet during acute shigellosis enhances growth in malnourished children. J Nutr 1997; 127:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/15\">",
"      Hossain S, Biswas R, Kabir I, et al. Single dose vitamin A treatment in acute shigellosis in Bangladesh children: randomised double blind controlled trial. BMJ 1998; 316:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/16\">",
"      Roy SK, Raqib R, Khatun W, et al. Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh. Eur J Clin Nutr 2008; 62:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/17\">",
"      Rabbani GH, Ahmed S, Hossain I, et al. Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial. Pediatr Infect Dis J 2009; 28:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/18\">",
"      Rabbani GH, Teka T, Zaman B, et al. Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology 2001; 121:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/19\">",
"      Rabbani GH, Teka T, Saha SK, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. Dig Dis Sci 2004; 49:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/20\">",
"      Kruse H, Kariuki S, S&oslash;li N, Olsvik O. Multiresistant Shigella species from African AIDS patients: antibacterial resistance patterns and application of the E-test for determination of minimum inhibitory concentration. Scand J Infect Dis 1992; 24:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/21\">",
"      Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 2003; 51:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/22\">",
"      Sivapalasingam S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother 2006; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/23\">",
"      Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/24\">",
"      Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; 2:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/25\">",
"      Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/26\">",
"      Cheasty T, Day M, Threlfall EJ. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy. Clin Microbiol Infect 2004; 10:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/27\">",
"      Rahman M, Shoma S, Rashid H, et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr 2007; 25:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/28\">",
"      Kuo CY, Su LH, Perera J, et al. Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect 2008; 41:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/29\">",
"      Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, et al. Macrolide-resistant Shigella sonnei. Emerg Infect Dis 2008; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: emergence of Shigella flexneri 2a resistant to ceftriaxone and ciprofloxacin --- South Carolina, October 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1619.",
"     </a>",
"    </li>",
"    <li>",
"     National Antimicrobial Resistance Monitoring System: Enteric Bacteria 2008. file://www.cdc.gov/narms/annual/2008/NARMS_2008_Annual_Report.pdf (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/32\">",
"      Wong MR, Reddy V, Hanson H, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/33\">",
"      Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis 2012; 54 Suppl 5:S458.",
"     </a>",
"    </li>",
"    <li>",
"     National Antimicrobial Resistance Monitoring System: Enteric Bacteria 2010. www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers--Kansas, Kentucky, and Missouri, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/36\">",
"      Rowe B, Threlfall EJ. Drug resistance in gram-negative aerobic bacilli. Br Med Bull 1984; 40:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/37\">",
"      Haltalin KC, Nelson JD, Ring R 3rd, et al. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/38\">",
"      Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo. Am J Dis Child 1972; 124:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/39\">",
"      Garcia de Olarte D, Trujillo H, Agudelo N, et al. Treatment of diarrhea in malnourished infants and children. A double-blind study comparing ampicillin and placebo. Am J Dis Child 1974; 127:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/40\">",
"      Nelson JD, Haltalin KC. Broad-spectrum penicillins in enteric infections of children. Ann N Y Acad Sci 1967; 145:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/41\">",
"      Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2009; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/42\">",
"      David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     Ashkenazi S. Shigella species. In: Antimicrobial therapy and vaccines, 2nd ed, Yu VL, Weer R, Raoult D (Eds), Apple Tree Production, New York 2002. p.615.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/44\">",
"      Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Shigella infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.645.",
"    </li>",
"    <li>",
"     Ashkenazi S, Cleary TG. Shigella species. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.819.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/47\">",
"      Eidlitz-Marcus T, Cohen YH, Nussinovitch M, et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993; 123:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/48\">",
"      Varsano, I, Eldlitz-Marcus, T, Nussinovitch, M, et al. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991; 118:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/49\">",
"      Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986; 29:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/50\">",
"      Lolekha S, Vibulbandhitkit S, Poonyarit P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis 1991; 13 Suppl 4:S342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/51\">",
"      Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/52\">",
"      Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/53\">",
"      Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/54\">",
"      Miron D, Torem M, Merom R, Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2004; 23:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/55\">",
"      Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/56\">",
"      Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/57\">",
"      Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2000; 19:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/58\">",
"      Bhattacharya K, Bhattacharya MK, Dutta D, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr 1997; 86:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/59\">",
"      Rogerie F, Ott D, Vandepitte J, et al. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986; 29:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/60\">",
"      Vinh H, Wain J, Chinh MT, et al. Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg 2000; 94:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/61\">",
"      Ashkenazi S, Amir J, Waisman Y, et al. A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr 1993; 123:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/62\">",
"      Helvaci M, Bekta��lar D, Ozkaya B, et al. Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children. Acta Paediatr Jpn 1998; 40:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/63\">",
"      Prado D, L&oacute;pez E, Liu H, et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992; 11:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/64\">",
"      Martin JM, Pitetti R, Maffei F, et al. Treatment of shigellosis with cefixime: two days vs. five days. Pediatr Infect Dis J 2000; 19:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/65\">",
"      Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995; 123:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/66\">",
"      Islam MR, Alam AN, Hussain MS, Mahalanabis D. Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it. J Trop Med Hyg 1995; 98:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/67\">",
"      Kagalwalla AF, Khan SN, Kagalwalla YA, et al. Childhood shigellosis in Saudi Arabia. Pediatr Infect Dis J 1992; 11:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/68\">",
"      Bennish ML, Salam MA, Wahed MA. Enteric protein loss during shigellosis. Am J Gastroenterol 1993; 88:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/69\">",
"      Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/70\">",
"      Gangaros EJ. Annotation: a community-focused strategy for the control of day-care center shigellosis. Am J Public Health 1995; 85:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8457/abstract/71\">",
"      Hoffman RE, Shillam PJ. The use of hygiene, cohorting, and antimicrobial therapy to control an outbreak of shigellosis. Am J Dis Child 1990; 144:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6003 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8457=[""].join("\n");
var outline_f8_16_8457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTROL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      School or day care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6003|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/5/29790\" title=\"figure 1\">",
"      Antimicrobial resistance pattern for Shigella US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=related_link\">",
"      Treatment and prevention of Shigella infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8458="Eustachian tube dysfunction";
var content_f8_16_8458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eustachian tube dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Dennis Poe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Bassem MN Hanna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/16/8458/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/16/8458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2342820\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The middle ear is an air-filled chamber within the skull that is periodically vented when the eustachian tube opens. Middle ear disease may be due, at least in part, to failure or inadequacy of eustachian tube function.",
"   </p>",
"   <p>",
"    There is no well-accepted definition of eustachian tube dysfunction, but it is commonly understood to mean that the eustachian tube has failed to provide adequate ventilation to the middle ear. However, this imprecise definition excludes the common condition of a patulous (chronically patent) eustachian tube. Eustachian tube dysfunction is more accurately defined as failure of the functional valve of the eustachian tube to open",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    close properly. &nbsp;",
"   </p>",
"   <p>",
"    This topic will discuss the pathophysiology, evaluation, and treatment of eustachian tube dysfunction. Specific diseases associated with eustachian tube dysfunction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link\">",
"     \"Otitis media with effusion (serous otitis media) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=see_link\">",
"     \"Chronic otitis media, cholesteatoma, and mastoiditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342827\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the anatomy and function of the eustachian tube is important to understanding its pathophysiology. The eustachian tube runs from the anterior wall of the middle ear cavity to open into the nasopharynx (",
"    <a class=\"graphic graphic_figure graphicRef66873 \" href=\"UTD.htm?29/39/30328\">",
"     figure 1",
"    </a>",
"    ). The nasopharyngeal and tympanic ends are wider than the middle of the tube, with the bony isthmus being the narrowest portion. The eustachian tube passes superiorly, posteriorly, and laterally from the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/1\">",
"     1",
"    </a>",
"    ]. Its total length in adults ranges 36 to 38 mm. Children have shorter, more horizontal tubes, immature floppy elastic cartilage, and larger adenoids compared to adults, which place them at a higher risk for obstruction and reflux of nasopharyngeal secretions and pathogens (",
"    <a class=\"graphic graphic_figure graphicRef63920 \" href=\"UTD.htm?37/47/38644\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The eustachian tube in children usually reaches adult length by age six.",
"   </p>",
"   <p>",
"    The eustachian tube is not just a static pipe; it is a dynamic organ having a lumen, skeleton, mucosal lining, and surrounding soft tissue and muscles (",
"    <a class=\"graphic graphic_figure graphicRef70595 \" href=\"UTD.htm?28/58/29604\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The skeleton of the tube is formed of cartilage in its inferior and medial two-thirds, and bone in the superior and lateral one-third. The bony portion lies within the petrous part of the temporal bone, while the cartilaginous portion is firmly attached superiorly to the sphenoid bone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6\">",
"     6",
"    </a>",
"    ]. The bony portion is normally patent and does not open and close dynamically as does the cartilaginous portion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/7\">",
"     7",
"    </a>",
"    ]. Within the bone and cartilage are the four muscles related to eustachian tube function: tensor veli palatini (TVP), levator veli palatini (LVP), tensor tympani, and salpingopharyngeus. The most important muscles for dilation are the TVP, the principal active tubal dilator, and the LVP, which sets the cartilaginous skeleton into position against which the TVP can complete the dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6\">",
"     6",
"    </a>",
"    ]. The anterolateral wall is membranous and consists of the luminal mucosa, submucosa, and the TVP muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/1\">",
"     1",
"    </a>",
"    ]. The lining of the eustachian tube is continuous with the rest of the respiratory tract.",
"   </p>",
"   <p>",
"    Viewing the eustachian tube orifice from the nasopharynx with an endoscope (",
"    <a class=\"graphic graphic_picture graphicRef53444 \" href=\"UTD.htm?43/37/44624\">",
"     picture 1",
"    </a>",
"    ), the lumen lies just anterior and lateral to the posterior cushion. The adenoid pad is situated in the midline of the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11700761\">",
"    <span class=\"h1\">",
"     NORMAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eustachian tube has three functional roles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Equalization of pressure across the tympanic membrane, which is considered the most important function of the eustachian tube as gas pressure homeostasis is essential for optimal hearing.",
"     </li>",
"     <li>",
"      Protecting the middle ear from infection and reflux of nasopharyngeal contents.",
"     </li>",
"     <li>",
"      Clearance of middle ear secretions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three functions are mediated by opening and closing of the eustachian tube (",
"    <a class=\"graphic graphic_picture graphicRef66208 \" href=\"UTD.htm?29/24/30080\">",
"     picture 2",
"    </a>",
"    ). The tube ordinarily opens with swallowing and yawning approximately 84 times per hour in the daytime, and less during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Not every swallow or yawn is accompanied with opening of the tube. The recoiling memory properties of the cartilaginous eustachian tube, relaxing bulk of the TVP muscle, and pressure of neighboring extraluminal tissue cause the tube to close passively. The lumen is likely maintained closed by these factors, as well as by the surface tension of the apposed wet mucosal surfaces, all in congregate serving as a functional valve that opens intermittently for ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/9\">",
"     9",
"    </a>",
"    ]. The valve is roughly 5 to 8 mm long in the middle of the cartilaginous portion of the tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11700640\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dysfunction can be separated into three pathologic processes: pressure dysregulation, impaired protective function, and diminished clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342881\">",
"    <span class=\"h2\">",
"     Pressure dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eustachian tube may fail to open adequately to allow for ventilation of the middle ear space, leading to pressure dysregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/4\">",
"     4",
"    </a>",
"    ]. Failure of the eustachian tube to open generally occurs due to functional or anatomic obstruction.",
"   </p>",
"   <p>",
"    Functional obstruction refers to compromise of tubal dilation in the absence of a physical blockage of the lumen. Chronic functional obstruction is most commonly due to mucosal inflammation with edema and secretions limiting the ability of the valve to open. Less commonly, failure of muscular actions may limit the dilatory ability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/8\">",
"     8",
"    </a>",
"    ]. A functionally impaired eustachian tube may be able to partially open, but the dilation may be insufficient to adequately ventilate the continually accumulating negative pressure within the middle ear. The negative pressure is induced by the chronic absorption of middle ear gases and can be exacerbated in the unnatural circumstances of descents during air travel and scuba diving. It can also occur secondary to habitual sniffing and thumb sucking with an obstructed nose. The negative pressure within the elastic eustachian tube makes it harder for the tubal muscles to dilate the lumen. Once excessively negative pressure occurs within the middle ear, it becomes a vicious cycle in which the absence of opening makes it increasingly difficult to dilate the tube, and the failure to open increases the negative pressure. Unless the cycle is stopped, pressures may exceed -400 mm H2O and cause fluid transudate to fill the vacuum. Conversely, positive middle ear pressure relative to ambient pressure, as occurs with ascending in the water or in the air, facilitates opening of the tubal lumen. A floppy tube (such as seen in young children with cleft palate, Down&rsquo;s syndrome, and other disorders with craniofacial anomalies) will tend to compress more readily with negative middle ear pressure, impairing the ability of the tube to dilate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    True anatomic obstruction occurs infrequently and may be due to unusually severe inflammation with swelling of mucosa, a large adenoid mass, congenital or acquired stenosis, or nasopharyngeal neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344336\">",
"    <span class=\"h2\">",
"     Impaired protective function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired protective function refers to reflux into the eustachian tube of nasopharyngeal pathogens, allergy-inducing proteins, gastric secretions, and sounds from one&rsquo;s own breathing or speaking (autophony). Reflux occurs in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormally patent eustachian tubes due to congenital or acquired factors.",
"     </li>",
"     <li>",
"      Short, floppy eustachian tubes, as in young children and patients with craniofacial anomalies. Bottle-fed children are exposed to higher risk compared to breast-fed children, especially if conventional non-ventilated bottles are used for feeding.",
"     </li>",
"     <li>",
"      Abnormal positive pressure in the nasopharynx can force material into the lumen. Nasopharyngeal obstruction, blowing the nose, and crying can induce abnormal positive pressures at the nasopharyngeal end of the tube.",
"     </li>",
"     <li>",
"      Loss of immune protection due to copious or viscous secretions may lead to failure to adequately expel pathogens from the middle ear.",
"     </li>",
"     <li>",
"      Loss of mucosal protection from gastric enzymes and acid. Nasopharyngeal and eustachian tube mucosa also do not contain the protective proteins found in the stomach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344353\">",
"    <span class=\"h2\">",
"     Impaired clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of mucociliary function can result in the inability to clear viscous material and pathogens from the middle ear. Such loss can occur from bacteria, bacterial toxins, viruses, smoking, toxic exposure, allergic disease, and other sources of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/11\">",
"     11",
"    </a>",
"    ]. Primary loss of mucociliary function occurs in cystic fibrosis and other ciliary dysmotility disorders. Ciliary function may be secondarily impaired in inflammatory conditions such as Samter&rsquo;s triad (ie, asthma, nasal polyps, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity). Impaired clearance may also be due to an obstructive process or inadequacy of tubal pump function (eg, due to muscle failure).",
"   </p>",
"   <p>",
"    Eustachian tube clearance can have postural variation as well. Venous engorgement occurs when the head is in a dependant position. This may not be physiologically significant in most people, but patients with a patulous eustachian tube (in which the valve fails to close) can find relief of their symptoms by lying supine. Seasonal variations in tubal function also occur in some patients, with eustachian tubes demonstrating better function in summer and fall than in winter and spring [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342888\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dysfunction represents a spectrum of disorders that can be broadly placed into two etiologic categories. Failure of tubal dilatory action is termed &lsquo;dilatory dysfunction,&rsquo; and valve incompetency leading to chronic patency (stuck open) is termed &lsquo;patulous dysfunction&rsquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/13\">",
"     13",
"    </a>",
"    ]. Dilatory dysfunction is responsible for a large proportion of otitis media and chronic ear disease and is much more common than patulous dysfunction. Patulous dysfunction can cause bothersome symptoms, but generally does not lead to any significant acute illness or chronic disease.",
"   </p>",
"   <p>",
"    In many cases, the etiology of eustachian tube dysfunction is not found, as the condition resolves spontaneously without ever being diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342897\">",
"    <span class=\"h2\">",
"     Dilatory dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several etiologies of dilatory failure of the eustachian tube in both adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any cause of inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infection, usually from the adenoids, nasopharynx, nose, and sinuses. Several chronic infections such as sinusitis are frequently associated with dilatory dysfunction and middle ear effusion.",
"     </li>",
"     <li>",
"      Allergies",
"     </li>",
"     <li>",
"      Irritants such as tobacco smoke, wood burning stoves, and pollution",
"     </li>",
"     <li>",
"      Laryngopharyngeal and gastroesophageal reflux",
"     </li>",
"     <li>",
"      Hormonal changes (eg, pregnancy, particularly in the third trimester when progesterone levels are peaking)",
"     </li>",
"     <li>",
"      Primary mucosal disease (eg, granulomatous disease, Samter&rsquo;s triad)",
"     </li>",
"     <li>",
"      Ciliary disorders (eg, primary ciliary dyskinesia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pressure dysregulation during scuba diving or descent during air travel (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"       \"Ear barotrauma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acquired anatomic abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nasopharyngeal masses, including neoplasms, can physically block the orifice, invade or compress the lumen, interfere with the dilatory tensor veli palatini (TVP) and levator veli palatini (LVP) muscles, or impinge on nerve supply.",
"     </li>",
"     <li>",
"      Trauma, such as with cleft palate surgery or intubation (nasogastric or nasal endotracheal), might lead to injury of the palatopterygoid bone or the eustachian tube itself. Injury to the trigeminal nerve or its mandibular branch can lead to functional obstruction.",
"     </li>",
"     <li>",
"      Hypertrophied adenoids may functionally or, more rarely, anatomically occlude the tubal orifice (",
"      <a class=\"graphic graphic_picture graphicRef79152 \" href=\"UTD.htm?39/62/40942\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital abnormalities include congenital cholesteatoma, dermoid cysts, cleft palates, and other craniofacial syndromes such as Down&rsquo;s, Crouzon, Apert, Treacher-Collins, and Turner syndromes.",
"     </li>",
"     <li>",
"      Degenerative and metabolic diseases affecting the tubal musculature (eg, myasthenia gravis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342904\">",
"    <span class=\"h2\">",
"     Patulous dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patulous dysfunction (chronic patency) is relatively benign (",
"    <a class=\"graphic graphic_picture graphicRef52732 \" href=\"UTD.htm?33/10/33952\">",
"     picture 4",
"    </a>",
"    ), and does not typically lead to ear complications or otitis media. Possible associated and causative factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/9,15-20\">",
"     9,15-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss, as little as a six pound reduction in weight, may be sufficient to produce significant tissue atrophy and patulous eustachian tubes. This may be due to a variety of chronic illnesses, especially rheumatologic diseases",
"     </li>",
"     <li>",
"      Scarring of mucosa as a result of previous procedures, inflammation, or radiation",
"     </li>",
"     <li>",
"      Neuromuscular disorders leading to muscle atrophy (eg, from cerebrovascular accidents, multiple sclerosis, poliomyelitis, traumatic injury to the trigeminal nerve)",
"     </li>",
"     <li>",
"      Allergy and chronic reflux of gastric contents, ultimately leading to mucosal atrophy",
"     </li>",
"     <li>",
"      Hormonal factors (high estrogen levels in pregnancy or high dose oral contraceptives in women, estrogen therapy for prostate cancer in men)",
"     </li>",
"     <li>",
"      Others &mdash; nasal decongestants or cocaine, craniofacial abnormalities, palatal myoclonus, chronic gum chewing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342911\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dysfunction is a clinical diagnosis, based upon history and physical examination. The diagnosis can be confirmed by nasal endoscopy and audiology studies. Other tests assessing for the etiology of the dysfunction are conducted based on the clinical situation (eg, allergy testing in a patient with persistent allergic symptoms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342918\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to inquire about specific symptoms (particularly those that may distinguish dilatory from patulous tubal dysfunction), underlying causes, and possible complications. (See",
"    <a class=\"local\" href=\"#H1596840350\">",
"     'Sequela and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms that may accompany dilatory dysfunction include ear pain, a sensation of ear fullness or pressure, hearing loss, and tinnitus. Patients commonly describe their ear(s) as feeling &ldquo;plugged.&rdquo; The patient might also report hearing popping and snapping noises that are associated with the opening of the tube with an unusually large change of pressure. Vertigo and disequilibrium may be reported in severe cases of negative pressure or in association with otitis media. Many patients, especially children, do not complain of ear problems, but are discovered to have an otitis media on routine checkups. Eustachian tube dysfunction may be suspected as a possible cause for delayed speech or language development or with failure of a school screening test for hearing.",
"   </p>",
"   <p>",
"    A seven-item scoring questionnaire for eustachian tube dysfunction has been proposed and contains the following seven attributes: ear pressure, ear pain, sensation of clogging, ear symptoms with a cold or sinusitis, popping or crackling sensation, ringing in the ear, and muffled hearing; it had reasonable validity in a small sample (n = 75) to distinguish patients with and without eustachian tube dysfunction, using tympanometry as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    History can also reveal a direct cause or exacerbating factor for the eustachian tube dysfunction. Nasal itch, frequent sneezing, and rhinorrhea are symptoms of allergy. Infections are characterized by production of colored nasopharyngeal discharge. Sore throat, cough, heartburn, frequent choking, and excessive salivation suggest laryngopharyngeal reflux. Nasal obstruction might be a symptom of a mass lesion, particularly if it is unilateral. Smoking or secondhand smoking may be a contributing factor.",
"   </p>",
"   <p>",
"    Eustachian tube dysfunction is the most important factor in the pathogenesis of middle ear infections. Acute otitis media episodes will be apparent having presented with fever and ear pain, but otitis media with effusion can be subtle and present with speech delays in children, hearing loss, and ear pressure or discomfort. Chronic or recurrent purulent otorrhea may indicate the presence of a tympanic membrane retraction pocket or cholesteatoma. (See",
"    <a class=\"local\" href=\"#H1596840350\">",
"     'Sequela and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In persistent cases, the patient should be asked about habits that may precipitate or exacerbate eustachian tube dysfunction, such as habitual sniffing or forceful attempts to aerate their middle ears and relieve the sense of",
"    <span class=\"nowrap\">",
"     pressure/obstruction.",
"    </span>",
"    Habitual sniffing can cause chronic negative pressure in the middle ear that leads to retraction or atelectasis of the tympanic membrane. Strong nose blows or raising nasopharyngeal pressure against a closed nose can force the eustachian tube open, but this repetition over time may distend and weaken the eustachian tube, or even result in a patulous tube.",
"   </p>",
"   <p>",
"    The hallmark symptom of patulous dysfunction of the eustachian tube is autophony: the patient complains about hearing",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own voice and breathing sounds greatly amplified, as if &ldquo;talking into a barrel.&rdquo; Hearing one&rsquo;s own voice is generally more bothersome than hearing one&rsquo;s own breathing sounds. Symptoms of patulous dysfunction often fluctuate and may be relieved with the head in a dependant position. They can be initiated or worsened by exercise and prolonged speaking as these activities cause dehydration of mucosa, and there can be a decongestive effect from the epinephrine-like hormones released with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with patulous dysfunction may also complain of ear fullness similar to those with dilatory dysfunction. Symptoms of patulous dysfunction can vary in severity from subtle to significantly bothersome, even to the point of being disabling, although patulous dysfunction does not lead to any significant disease in the middle ear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342934\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A head and neck examination should be performed on every patient with a possible eustachian tube problem. Particular attention should be given to the ear examination as this is most likely to detect any underlying etiology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications of eustachian tube dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ear examination is done using an otoscope. Normally the tympanic membrane has a shiny translucent appearance (",
"    <a class=\"graphic graphic_picture graphicRef52626 \" href=\"UTD.htm?5/14/5345\">",
"     picture 5",
"    </a>",
"    ). A dull bluish gray or yellowish coloration denotes an effusion behind the membrane. Reddish coloration and engorged vessels could be a sign of inflammation, although straining of a child during crying or blowing the nose can also lead to engorged tympanic vessels. The reflection of the light on the anteroinferior quadrant of the tympanic membrane is not a reliable indicator of changes in the drum or its position, as it is often present despite significant pathology. Scarring and thickening of the tympanic membrane can alter the shape of the cone of light, so the entire tympanic membrane should be evaluated systematically.",
"   </p>",
"   <p>",
"    The short process of malleus is visible as a mild protrusion near the &ldquo;twelve-o-clock&rdquo; position in the healthy transparent tympanic membrane (",
"    <a class=\"graphic graphic_picture graphicRef52626 \" href=\"UTD.htm?5/14/5345\">",
"     picture 5",
"    </a>",
"    ). In cases of high negative pressures, the tympanic membrane is retracted and the short process is more prominent, and the manubrium (or handle) of the malleus appears shorter because it is medially rotated (",
"    <a class=\"graphic graphic_picture graphicRef52819 \" href=\"UTD.htm?18/49/19217\">",
"     picture 6",
"    </a>",
"    ). Presence of middle ear effusion may obscure the view of the short process. The fullness or retraction of the tympanic membrane is most clearly appreciated at the posterosuperior aspect, as it has the highest compliance.",
"   </p>",
"   <p>",
"    The tympanic membrane is examined for any retractions (",
"    <a class=\"graphic graphic_picture graphicRef52819 \" href=\"UTD.htm?18/49/19217\">",
"     picture 6",
"    </a>",
"    ), effusions (",
"    <a class=\"graphic graphic_picture graphicRef67379 \" href=\"UTD.htm?20/6/20576\">",
"     picture 7",
"    </a>",
"    ), atelectasis (",
"    <a class=\"graphic graphic_picture graphicRef78843 \" href=\"UTD.htm?4/0/4098\">",
"     picture 8",
"    </a>",
"    ), cholesteatomas (",
"    <a class=\"graphic graphic_picture graphicRef59937 \" href=\"UTD.htm?20/54/21344\">",
"     picture 9",
"    </a>",
"    ), perforations (",
"    <a class=\"graphic graphic_picture graphicRef64202 \" href=\"UTD.htm?27/15/27888\">",
"     picture 10",
"    </a>",
"    ), or tympanosclerotic plaques. Any of these signs can be associated with dilatory eustachian tube dysfunction. Normal otoscopic findings do not necessarily mean the absence of eustachian tube disease.",
"   </p>",
"   <p>",
"    The examination is greatly aided with a pneumatic otoscope that allows for insufflation (",
"    <a class=\"graphic graphic_picture graphicRef63633 \" href=\"UTD.htm?38/53/39774\">",
"     picture 11",
"    </a>",
"    ). With gentle application of positive and then negative pressure by the pneumatic otoscope, the normal drum moves inwards then outwards respectively (",
"    <a class=\"graphic graphic_movie graphicRef55117 \" href=\"UTD.htm?34/4/34895\">",
"     movie 1",
"    </a>",
"    ). The movement of the drum is most evident posterosuperiorly. A fluid-filled middle ear will minimize any tympanic membrane excursions with insufflation (",
"    <a class=\"graphic graphic_movie graphicRef67928 \" href=\"UTD.htm?21/56/22415\">",
"     movie 2",
"    </a>",
"    ). When there is negative pressure within the middle ear, the retracted tympanic membrane will mobilize laterally and become more compliant with the application of negative pressure insufflation. Newborn infants have a thicker and more opaque tympanic membrane than older infants and children. Thus, care should be taken during otoscopy not to mistake them for being retracted.",
"   </p>",
"   <p>",
"    When there is an actively patulous eustachian tube, excursions of the tympanic membrane will accompany the patient&rsquo;s breathing, especially if the opposite nostril is held closed. Lying in the supine position may temporarily close the patulous defect and stop the breathing-induced excursions.",
"   </p>",
"   <p>",
"    When hearing loss is present, patients should undergo further evaluation which may include the use of tuning forks to determine whether there is conductive versus sensorineural hearing loss. Conductive hearing loss may occur with dilatory, but not with patulous dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other components of the physical examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nasal cavity should be inspected for abnormalities, including evidence of inflammation, allergic changes, masses, bleeding, granulomatous disease, and polyps.",
"     </li>",
"     <li>",
"      The neck should be examined for enlarged lymph nodes, masses, or congenital cysts. These findings may accompany inflammatory conditions or neoplasms, especially nasopharyngeal tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964211772\">",
"    <span class=\"h2\">",
"     Nasal endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dysfunction can be further assessed by an otolaryngologist with a detailed nasopharyngeal examination, preferably performed with flexible or rigid nasal endoscopy. (See",
"    <a class=\"local\" href=\"#H2344727\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In our experience, it is useful to start the examination with the flexible endoscope and, if more detailed views are needed, then the rigid endoscopes may provide the optimal view. The flexible endoscope is used to survey the nasal cavity in detail and to inspect the sinus orifices for inflammation, secretions, or allergic manifestations. The nasopharynx is also examined for evidence of enlarged or inflamed adenoids or other masses. The relationship of any adenoidal mass to the posterior cushion is noted to see if it may cause impingement on tubal opening at rest or with swallowing. The best view into the eustachian tubal lumen is often obtained by passing the flexible endoscope from the contralateral nares, curving around the vomer bone to come in line with the longitudinal axis of the eustachian tube (",
"    <a class=\"graphic graphic_picture graphicRef52732 \" href=\"UTD.htm?33/10/33952\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79152 \" href=\"UTD.htm?39/62/40942\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53444 \" href=\"UTD.htm?43/37/44624\">",
"     picture 1",
"    </a>",
"    ). Patients are asked to perform a series of swallows and yawns to assess the quality of opening of the tube (",
"    <a class=\"graphic graphic_picture graphicRef66208 \" href=\"UTD.htm?29/24/30080\">",
"     picture 2",
"    </a>",
"    ). The endoscope is passed towards the oropharynx, hypopharynx, and larynx to check for evidence of reflux, such as thickening, edema, and erythema of the vocal cords.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342948\">",
"    <span class=\"h2\">",
"     Audiometric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tympanogram to measure the middle ear pressure and pure tone audiometry to assess for hearing loss are important tools in evaluation of eustachian tube dysfunction. In a child with persistent symptoms, an audiogram and tympanogram should be repeated after three months at which time the decision to perform tympanostomy tubes may be made. In adults, a follow-up audiogram and tympanogram may be done after 3 to 12 months depending on the severity of symptoms and whether any improvement is occurring or anticipated. Persistent, severe symptoms in an adult would prompt a follow-up audiogram and tympanogram after three months with consideration for more aggressive medical care or a tympanostomy tube.",
"   </p>",
"   <p>",
"    Tympanometry is a reliable instrument that determines normal versus abnormal pressures within the middle ear. Tympanometry can indirectly measure middle ear pressure by comparing changes in compliance of the tympanic membrane to changes in external ear canal pressure. The presence of middle ear effusion stiffens the system (decreases the compliance). Actively patulous eustachian tubes can sometimes be identified on tympanometry by sawtoothed changes in compliance as the patient&rsquo;s breathing causes shifts in middle ear pressure.",
"   </p>",
"   <p>",
"    Audiometry is important in measuring the impact that eustachian tube dysfunction may have on hearing function, but it does not correlate with severity of tubal pathology. Mild to moderate conductive hearing loss is expected in cases of atelectasis and middle ear effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344874929\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT or MRI scan with contrast is indicated in patients with more than three months of unilateral symptoms or a middle ear effusion. These raise suspicion for a neoplasm that may be obstructing the eustachian tube and should be evaluated with diagnostic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342969\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many diseases can cause hearing loss, tinnitus, or ear",
"    <span class=\"nowrap\">",
"     fullness/pain.",
"    </span>",
"    The evaluation of these symptoms is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=see_link\">",
"     \"Evaluation of earache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to considering eustachian tube dysfunction and its associated etiologies, important conditions that can mimic eustachian tube dysfunction include (see",
"    <a class=\"local\" href=\"#H2342888\">",
"     'Etiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporomandibular joint dysfunction &mdash; Temporomandibular joint dysfunction (TMJ) produces ear blockage symptoms that are commonly misdiagnosed as eustachian tube dysfunction. In TMJ, there can be pain deep within the ear, tenderness around the ear canal or pre-auricular area, or headaches. TMJ is also accompanied by tenderness just posteriorly and superiorly within the joint space that occurs with mouth opening. Intraoral exam will usually reveal significant tenderness over the pterygoid muscles that can be palpated where they insert into the mandible (",
"      <a class=\"graphic graphic_picture graphicRef55205 \" href=\"UTD.htm?1/60/1999\">",
"       picture 12",
"      </a>",
"      ). Furthermore, in contrast to patients with eustachian tube dysfunction, otoscopic examination, pneumatic insufflation, and tympanometry will be normal despite the patient&rsquo;s active &ldquo;ear&rdquo; complaints, which should raise suspicion about the possibility of TMJ. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7194?source=see_link\">",
"       \"Temporomandibular joint dysfunction syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meniere disease &mdash; Patients with early Meniere disease may present with a sensation of fluctuating ear blockage, with or without accompanying fluctuating hearing loss. The ear examination and tympanometry will be normal in most cases. The diagnosis is made by observing the patient as symptoms spontaneously fluctuate over time. Audiometric testing during exacerbations may confirm the diagnosis by showing a characteristic low frequency sensorineural hearing loss. In contrast to the relatively stable symptoms of eustachian tube dysfunction over time, advanced cases of Meniere disease will be more likely to exhibit the classical episodic fluctuating symptoms of ear fullness, sensorineural hearing loss, tinnitus, and vertigo. Vestibular function tests may be normal early in the course of Meniere disease, but will eventually be abnormal on the affected side. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link&amp;anchor=H5#H5\">",
"       \"Meniere disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Superior semicircular dehiscence (Minor's) syndrome &mdash; Superior semicircular dehiscence or &lsquo;Minor&rsquo;s syndrome&rsquo; is a dehiscence in the bone that normally separates the superior semicircular canal from the middle cranial fossa. It can present with variable symptoms that can be confused with eustachian tube dysfunction. There can be ear blockage, disequilibrium, vertigo with loud noises, conductive hearing loss, and enhanced perception of internal sounds such as one&rsquo;s own voice (autophony) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/23-26\">",
"       23-26",
"      </a>",
"      ]. The diagnosis can be established with an MRI or high resolution CT of the temporal bone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/27\">",
"       27",
"      </a>",
"      ]. Some patients benefit by surgical repair of the anatomical deficit [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Semicircular canal dehiscence syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342997\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of eustachian tube dysfunction should be directed at the underlying etiology, if known, and any associated complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6\">",
"     6",
"    </a>",
"    ]. The choice of management strategies for isolated eustachian tube dysfunction remains controversial as randomized trial data are limited, study outcomes vary widely between studies, and much of what is known about the treatment of eustachian tube dysfunction comes from animal rather than human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a systematic review of 34 observational studies and randomized trials assessing a variety of interventions (eg, decongestants, antibiotics, surgery), several studies demonstrated beneficial effects for some aspects of tubal function (mostly ventilatory function) and detrimental effects for others (mostly protective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clearance functions) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/29\">",
"     29",
"    </a>",
"    ]. However, there was no intervention that was consistently effective in improving tubal function. Furthermore, as the primary outcome measures in these studies were measures of tubal function, it is not clear if treatments ultimately lead to improved symptoms or prevention of illness.",
"   </p>",
"   <p>",
"    In treating eustachian tube dysfunction, dilatory dysfunction should be differentiated from patulous dysfunction during the clinical evaluation. Dilatory dysfunction is best differentiated by accompanying symptoms of hearing loss and abnormalities of the tympanic membrane such as retraction or middle ear effusion. Patulous dysfunction should be suspected when the primary complaint is autophony (hearing one&rsquo;s own voice and breathing sounds), yet there is no complaint of hearing loss and the tympanic membrane appears normal. Clinicians may be tempted to consider patients complaining of ear blockage as having dilatory dysfunction. However, ear blockage can occur in both dilatory and patulous dysfunction. Dilatory dysfunction treatments for patulous dysfunction will fail to help and may even exacerbate the symptoms. (See",
"    <a class=\"local\" href=\"#H2342911\">",
"     'Clinical evaluation'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2343018\">",
"    <span class=\"h2\">",
"     Dilatory dysfunction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596840563\">",
"    <span class=\"h3\">",
"     Underlying etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dilatory dysfunction is most commonly caused by inflammation related to underlying etiology. A careful search for the cause with appropriate therapy is usually successful in improving eustachian tube function. There are many possible causes for dilatory dysfunction, most of which will respond to treatment. In the absence of bacterial infection, systemic decongestants (most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ), antihistamines, or nasal steroid sprays are frequently prescribed to treat presumptive viral rhinosinusitis or allergic rhinitis.",
"   </p>",
"   <p>",
"    The most common etiologies of dilatory dysfunction and their treatments include (see",
"    <a class=\"local\" href=\"#H2342888\">",
"     'Etiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhinosinusitis &mdash; Treatment for viral rhinosinusitis and mild cases of bacterial rhinosinusitis is usually directed at symptom management. Moderate to severe cases of acute bacterial rhinosinusitis are usually treated with narrow spectrum antibiotics. Multiple therapies are utilized in the management of chronic rhinosinusitis, including intranasal saline, topical and systemic glucocorticoids, antibiotics, leukotriene inhibitors, and antifungals. These treatments are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"       \"Management of chronic rhinosinusitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"       \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergic and nonallergic rhinitis &mdash; Allergies can be partly controlled by avoidance of the offending agent, if known. The decision to use pharmacotherapy varies based on patient age, severity of symptoms, and comorbidities (eg, asthma, nasal polyposis). Antihistamines, topical nasal steroid sprays or cromolyn, oral leukotriene inhibitors, or combinations of these treatments are commonly effective in treating allergic symptoms. Immunotherapy can be helpful in refractory cases. Counseling for smoking cessation and the hazards of secondhand smoking should also be offered to the patient. In children over six years old with otitis media with effusion, allergies should be strongly suspected. Many patients with vasomotor rhinitis may have allergies that have not been identified by testing and may respond to the above measures as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27925?source=see_link\">",
"       \"Immunologic treatments for allergic rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"       \"Chronic nonallergic rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"       \"Secondhand smoke exposure: Effects in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"       \"Secondhand smoke exposure: Effects in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laryngopharyngeal reflux &mdash; Treatment should begin with behavioral modification. This includes avoidance of caffeine, alcohol, chocolate, peppermints, carbonated beverages, nicotine, and spicy foods. Patients should eat smaller meals and avoid eating immediately before exercise or sleep. Patients with concomitant laryngopharyngeal and gastroesophageal reflux (GERD) should be treated with proton pump inhibitors. For all other patients, in the absence of symptomatic GERD, acid-blocking therapy is generally not helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link&amp;anchor=H14#H14\">",
"       \"Laryngopharyngeal reflux\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mass lesions &mdash; Mass lesions blocking the eustachian tube are treated according to the nature of the mass. Adenoid hypertrophy is the most common entity in which the adenoid either physically impairs the opening of the tubal orifice or it may contribute to inflammation within the eustachian tube. Excision of enlarged adenoids is effective in reducing the incidence of otitis media with effusion, especially in children. Tumors are uncommon but should be suspected in cases of persistent unilateral symptoms. Nasopharyngeal carcinoma, the most common malignancy affecting the eustachian tube, is usually treated with radiation therapy, without surgical resection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiologies of nasal symptoms: An overview\", section on 'Enlarged adenoids'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link\">",
"       \"Tonsillectomy and adenoidectomy in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344641\">",
"    <span class=\"h3\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal treatment should be directed toward the suspected etiology of tubal dysfunction. (See",
"    <a class=\"local\" href=\"#H1596840563\">",
"     'Underlying etiologies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is little evidence to support the use of pharmacologic therapies for isolated eustachian tube dysfunction (ie, not associated with the conditions described above) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/29\">",
"     29",
"    </a>",
"    ]. In our practice, we have found that systemic decongestants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    may be helpful for congestive symptoms (eg, ear fullness or pressure), particularly in patients with a retracted tympanic membrane. Systemic or topical decongestants are not effective in cases of otitis media with effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Topical nasal decongestant sprays or drops may be used on a limited basis (generally three days or less) for symptomatic relief of nasal congestion or rhinitis, with or without ear blockage symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/33\">",
"     33",
"    </a>",
"    ]. Topical decongestants may also be helpful for difficulty clearing the ears during flights and scuba diving. Patients should be counseled not to exceed three days of nasal decongestant treatment, in order to avoid nasal mucosal dependency and rhinitis medicamentosa. Animal studies have found that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , taken in a tapered dose, may be effective in relieving effusion and improving acute eustachian tube dilatory dysfunction, but human studies are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/34\">",
"     34",
"    </a>",
"    ]. Topical steroid drops are being used in Europe, but the efficacy has not been established. Inhalation of steam is often suggested, but has not been studied.",
"   </p>",
"   <p>",
"    Insufflation of the eustachian tube by applying positive pressure to the eustachian tube orifice through the nasal cavity (Politzer maneuver) can temporarily relieve negative middle ear pressure, but these efforts are impractical for long-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Politzer devices for office or home use are available by prescription. One prospective cohort study found that adults with eustachian tube dysfunction following airplane travel had normalization of tympanometric pressures following use of a politzer device for eustachian tube insufflation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/37\">",
"     37",
"    </a>",
"    ]. A systematic review of six randomized trials found that Politzer devices are effective for treatment of otitis media with effusion in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/36\">",
"     36",
"    </a>",
"    ]; however, these trials did not assess other forms of eustachian tube dysfunction and did not evaluate adults. Thus, it is uncertain which patients with eustachian tube dysfunction would be most likely to benefit from Politzer devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344648\">",
"    <span class=\"h3\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is generally indicated when medical management fails. As an example, in children with otitis media with effusion thought secondary to eustachian tube dysfunction, tympanostomy tubes are indicated for persistence over 90 days despite medical therapy.",
"   </p>",
"   <p>",
"    The indication for tympanostomy tubes in adults is more variable, depending upon the severity of symptoms and likelihood of improvement. Tympanostomy tubes neutralize the negative pressure within the middle ear, providing relief from the effects of dilatory dysfunction. Tympanostomy tubes are effective in preventing sequela of negative pressure and, in most cases, any effusion will not recur upon extrusion of the tube. However, when tubal pathology persists, recurrence of signs and symptoms is likely to occur. Additional tubes may be performed as needed. Longer-term tympanostomy tubes may be used that typically remain in place for several years but have a higher risk for subsequent tympanic membrane perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eustachian tuboplasty is a procedure that reduces the thickness of the mucosa and submucosa of the more bulky posterior-medial wall of the tubal orifice and lumen in order to facilitate tubal dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/7\">",
"     7",
"    </a>",
"    ]. Small case series have shown that eustachian tuboplasty may be modestly effective in treating tubal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balloon dilation is a novel method being studied to increase the patency of the cartilaginous eustachian tube. Similar to the concept of balloon sinuplasty for the treatment of chronic sinusitis, a balloon catheter is used to dilate the cartilaginous portion through a minimally invasive transnasal endoscopic approach (",
"    <a class=\"graphic graphic_picture graphicRef83639 \" href=\"UTD.htm?39/56/40834\">",
"     picture 13",
"    </a>",
"    ). Initial cadaveric studies and clinical trials are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2343040\">",
"    <span class=\"h2\">",
"     Patulous dysfunction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596840742\">",
"    <span class=\"h3\">",
"     Underlying etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be directed at underlying medical conditions, if known. (See",
"    <a class=\"local\" href=\"#H2342888\">",
"     'Etiology'",
"    </a>",
"    above.) Although many patients have experienced a significant weight loss with their illness, weight gain is rarely effective and is generally not recommended unless the patient is physiologically underweight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344692\">",
"    <span class=\"h3\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with patulous dysfunction have often been given decongestants or nasal steroid therapy empirically, and these should be discontinued as they are not effective and may worsen symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients who have mild symptoms only require reassurance about the benign nature of patulous dysfunction. Patulous symptoms often fluctuate, depending on the patient&rsquo;s medical condition and any dehydration. Medical therapy should be initiated for patients having severe symptoms lasting more than six weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good hydration can be effective and may be supplemented by nasal saline drops as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/43\">",
"       43",
"      </a>",
"      ]. To achieve the best result, the drops should come in contact with the tubal orifice. Patients are instructed to raise their nose straight up, place the drops, then tilt the head to the diseased side. Saline irrigations may be tried when drops are not sufficiently effective.",
"     </li>",
"     <li>",
"      When hydration and topical therapy are ineffective, thickening of the mucus can be attempted using potassium iodine eight to ten drops in a glass of juice taken orally three times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344699\">",
"    <span class=\"h3\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is reserved for patients with severe symptoms who do not respond to medical management (ie, treatment of underlying etiology, hydration, and potassium iodine).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tympanostomy tube insertion may be offered to patients as first-line surgical treatment, as other surgical treatments are new and not widely available. Tubes can",
"      <strong>",
"      </strong>",
"      provide some relief in approximately half of treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/44\">",
"       44",
"      </a>",
"      ]. They are only effective in relieving the bothersome sensation of movements of the tympanic membrane during breathing, but not in improving autophony, which is usually the main complaint.",
"     </li>",
"     <li>",
"      Intraluminal catheter placement &mdash; An intravenous catheter sealed with bone wax is a method to block the wide eustachian tube by plugging its lumen (",
"      <a class=\"graphic graphic_picture graphicRef72681 \" href=\"UTD.htm?27/26/28064\">",
"       picture 14",
"      </a>",
"      ). The catheter wedges into the isthmus but does not completely obstruct the tube, and a sufficient amount of air can be exchanged around the catheter. Several case reports show that this method can be effective in eliminating or reducing the bothersome patulous autophony in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/6,16,45\">",
"       6,16,45",
"      </a>",
"      ]. The catheter is inert and can stay in place for long periods of time.",
"     </li>",
"     <li>",
"      Cartilage grafting &mdash; This approach is generally used after failure of intraluminal catheters. Endoscopic approaches are used for reconstruction of the patulous defect while preserving the eustachian tube&rsquo;s function. The technique implants conchal or septal cartilage grafts to augment the concave defect within the anterolateral wall. Although long-term data are not yet available, patients followed for five years demonstrate that the procedure is efficacious, but some symptoms recur in about 50 percent of patients after two years of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complete occlusion of the eustachian tube &mdash; Occlusion of the eustachian tube is effective in relieving symptoms, but it is only done as a last resort in patients who are intolerant of persistent symptoms despite other treatment. The ear will usually require tympanostomy tubes indefinitely in order to avoid complications of severe tympanic membrane retraction, permanent effusion, or cholesteatoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/16,19\">",
"       16,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Curvature inversion technique",
"      <strong>",
"       &mdash;",
"      </strong>",
"      KTP laser is used to cross-hatch the medial cartilaginous lamina to reverse the curvature of the cushion of the nasopharyngeal orifice, resulting in a narrowing of the eustachian tube orifice and valve and restoration of the competency of the valve to close. This method is still in early trials [",
"      <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596840350\">",
"    <span class=\"h1\">",
"     SEQUELA AND COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531862\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial stages of eustachian tube dysfunction, the retracted tympanic membrane or middle ear effusion will cause a conductive hearing loss. Restoration of tubal function at this stage will usually reverse the hearing loss and permit normal hearing function. If eustachian tube dysfunction continues, permanent injury may occur to the tympanic membrane from retraction, in which case full restoration of the conductive hearing loss is not always possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531869\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media, occurring as a complication of eustachian tube dysfunction, is usually self-limited, but antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy directed at symptom relief may be used. Antibiotic treatment is used for treatment of acute otitis media. In otitis media with effusion, topical decongestants and antihistamines are commonly used for temporary symptomatic relief, but there is little evidence that these agents are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/16/8458/abstract/32\">",
"     32",
"    </a>",
"    ]. Children that continue to have recurrent otitis media should be suspected of ongoing factors that could contribute to otitis media such as allergic disease, laryngopharyngeal reflux, or immune deficiency. Treatment of otitis media is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=see_link\">",
"     \"Chronic otitis media, cholesteatoma, and mastoiditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=see_link\">",
"     \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531876\">",
"    <span class=\"h2\">",
"     Tympanic membrane perforations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanic membrane perforations will often heal spontaneously. For most patients with acute rupture of the tympanic membrane, treatment consists of antibiotics and preventing water from entering the ear canal. Patients with severe symptoms (eg, significant hearing loss, otorrhea, nystagmus) or persistent perforation should be referred to an otolaryngologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation and management of middle ear trauma\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531883\">",
"    <span class=\"h2\">",
"     Cholesteatomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent inflammation within the middle ear and tympanic membrane due to eustachian tube dysfunction may lead to the formation of retraction pockets that develop retention of debris and progressive deepening of the pockets into the roof of the middle ear and mastoid cavity. This may eventually become a continually expanding cyst of squamous epithelium, known as a cholesteatoma. Cholesteatomas are potentially destructive to the middle and inner ear, especially when they get infected. Cholesteatomas should be referred to an otolaryngologist for surgical removal, usually in conjunction with tympanoplasty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link&amp;anchor=H16#H16\">",
"     \"Cholesteatoma in children\", section on 'Surgical treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=see_link&amp;anchor=H26969917#H26969917\">",
"     \"Chronic otitis media, cholesteatoma, and mastoiditis in adults\", section on 'Cholesteatoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344727\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for referral to an otolaryngologist include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe ear complaints including significant hearing loss or intense ear pain",
"     </li>",
"     <li>",
"      The patient is not improving or has worsening symptoms despite medical treatment",
"     </li>",
"     <li>",
"      Presence of cholesteatoma, recurrent otitis media, persistent effusion or tympanic membrane perforation",
"     </li>",
"     <li>",
"      Persistent unilateral otitis media with effusion, which may indicate severe disease (eg, neoplasm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to an allergist for further evaluation is especially appropriate in children with persistent allergic symptoms who have not outgrown their eustachian tube dysfunction by age six.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=see_link\">",
"       \"Patient information: Eustachian tube problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2343047\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three main functions of the eustachian tube include pressure regulation, protection of the middle ear, and mucociliary clearance. Eustachian tube dysfunction can predispose to middle ear disease. (See",
"      <a class=\"local\" href=\"#H11700761\">",
"       'Normal function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11700640\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eustachian tube dysfunction represents a spectrum of disorders that can be broadly placed into two etiologic categories. Failure of tubal dilatory action is termed &ldquo;dilatory dysfunction,&rdquo; and valve incompetency leading to chronic patency (stuck open) is termed &ldquo;patulous dysfunction.&rdquo; (See",
"      <a class=\"local\" href=\"#H2342888\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eustachian tube dysfunction is a clinical diagnosis, mainly based on history and physical examination. Dilatory dysfunction should be differentiated from patulous dysfunction during the clinical evaluation, as medical therapies differ. Dilatory dysfunction is best differentiated by accompanying symptoms of hearing loss and abnormalities of the tympanic membrane such as retraction or middle ear effusion. Patulous dysfunction should be suspected when the primary complaint is autophony (hearing one&rsquo;s own voice and breathing sounds), yet there is no complaint of hearing loss and the tympanic membrane appears normal. The diagnosis can be confirmed by nasal endoscopy and audiology studies. A head and neck examination should be performed in patients with a possible eustachian tube problem. Particular attention should be given to the ear examination as this is most likely to detect any underlying etiology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications of eustachian tube dysfunction. (See",
"      <a class=\"local\" href=\"#H2342911\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of eustachian tube dysfunction should be directed at the underlying etiology, if known. There are many causes of dilatory dysfunction (including rhinosinusitis, allergic rhinitis, and tumors) that will respond to specific treatment. In the absence of an underlying cause of dilatory dysfunction, systemic decongestants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      may be helpful for congestive symptoms (eg, ear fullness or pressure). Patients should be counseled not to exceed three days of nasal decongestant treatment, in order to avoid nasal mucosal dependency and rhinitis medicamentosa. (See",
"      <a class=\"local\" href=\"#H2343018\">",
"       'Dilatory dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical management of patients with patulous dysfunction includes hydration and mucus-thickening agents. Decongestants should be avoided because they are not effective and may worsen symptoms. Surgical management includes tympanostomy tube insertion, cartilage grafting, intraluminal catheter placement, and complete occlusion of the eustachian tube. (See",
"      <a class=\"local\" href=\"#H2343040\">",
"       'Patulous dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of eustachian tube dysfunction include hearing loss, otitis media, tympanic membrane perforation, and cholesteatomas. (See",
"      <a class=\"local\" href=\"#H1596840350\">",
"       'Sequela and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be referred to an otolaryngologist if they have severe symptoms (hearing loss, persistent ear pain),",
"      <span class=\"nowrap\">",
"       persistent/worsening",
"      </span>",
"      symptoms or signs despite medical therapy, or complication that may require surgical treatment (eg, cholesteatoma, perforated tympanic membrane). (See",
"      <a class=\"local\" href=\"#H2344727\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bluestone, CD. Eustachian Tube. Structure, Function, Role in Otitis Media, BC Decker Inc., 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/2\">",
"      Bluestone CD. Studies in otitis media: Children's Hospital of Pittsburgh-University of Pittsburgh progress report--2004. Laryngoscope 2004; 114:1.",
"     </a>",
"    </li>",
"    <li>",
"     Healy, GB, Rosbe, KW. Otitis media and Middle Ear Effusions. In: Ballenger&rsquo;s Otorhinolaryngology Head and Neck Surgery, 16, Snow, JB Jr, Ballenger, JJ (Eds), BC Decker, Inc, 2003. p.249.",
"    </li>",
"    <li>",
"     Bluestone, CD, Klein, JO. Otitis media and Eustachian tube dysfunction. In: Pediatric Otolaryngology, 4, Bluestone, CD, Sylven, SE, Alper, CM, et al (Eds), W.B. Saunders, 2003. p.474.",
"    </li>",
"    <li>",
"     Bluestone, CD. Anatomy and Physiology Of The Eustachian Tube. In: Head &amp; Neck Surgery &ndash; Otlaryngology, 1, 2, Baily, BJ (Eds), Lippincott - Raven, 1998. p.1285.",
"    </li>",
"    <li>",
"     Poe, DS, Gopen, Q. Eustachian Tube Dysfunction. In: Ballenger&rsquo;s Textbook of Otolaryngology, Wackym, PA (Eds), BC Decker, Toronto 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/7\">",
"      Hopf J, Linnarz M, Gundlach P, et al. [Microendoscopy of the Eustachian tube and the middle ear. Indications and clinical application]. Laryngorhinootologie 1991; 70:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/8\">",
"      Poe DS, Abou-Halawa A, Abdel-Razek O. Analysis of the dysfunctional eustachian tube by video endoscopy. Otol Neurotol 2001; 22:590.",
"     </a>",
"    </li>",
"    <li>",
"     Handzel, O, Poe, DS. The Diagnosis and Management of the Patulous Eustachian Tube. In: Otologic Surgery, Brackmann, Shelton, Arriaga (Eds), Elvester Pub, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/10\">",
"      Bylander A, Tjernstr&ouml;m O, Ivarsson A. Pressure opening and closing functions of the Eustachian tube by inflation and deflation in children and adults with normal ears. Acta Otolaryngol 1983; 96:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/11\">",
"      Licameli GR. The eustachian tube. Update on anatomy, development, and function. Otolaryngol Clin North Am 2002; 35:803.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Otitis media in Infants and Children, 4th, BC Becker, Inc., Hamilton 2007.",
"    </li>",
"    <li>",
"     Poe DS, Gopen Q. Medical and Surgical Management of Eustachian Tube Dysfunction: Mucosal Disorders. In: Chronic Otitis Media,  Pathology-guided,pPathogenesis-oriented treatment, Ars B (Ed), Kugler Press, 2007.",
"    </li>",
"    <li>",
"     Bluestone, CD, Klein, JO. Otitis media, atelectasis, and Eustachian tube dysfunction. In: Pediatric otolaryngology, 1, 3, Bluestone, CD, Stool, SE, Kenna, MA (Eds), W.B. Saunders, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/15\">",
"      Pulec JL. Abnormally patent eustachian tubes: treatment with injection of polytetrafluoroethylene (Teflon) paste. Laryngoscope 1967; 77:1543.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone, CD, Magit, AE. The abnormally patulous Eustachian tube. In: Otologic Surgery, Brackmann, Shelton, Arriaga (Eds), W.B. Saunders, 1994. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/17\">",
"      Doherty JK, Slattery WH 3rd. Autologous fat grafting for the refractory patulous eustachian tube. Otolaryngol Head Neck Surg 2003; 128:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/18\">",
"      O'Connor AF, Shea JJ. Autophony and the patulous eustachian tube. Laryngoscope 1981; 91:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/19\">",
"      Poe DS. Diagnosis and management of the patulous eustachian tube. Otol Neurotol 2007; 28:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/20\">",
"      Hazell JW. Tinnitus. II: Surgical management of conditions associated with tinnitus and somatosounds. J Otolaryngol 1990; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/21\">",
"      McCoul ED, Anand VK, Christos PJ. Validating the clinical assessment of eustachian tube dysfunction: The Eustachian Tube Dysfunction Questionnaire (ETDQ-7). Laryngoscope 2012; 122:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/22\">",
"      Kalaida PH. The COMPLETE exam for otitis. Contemp Pediatr 1997; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/23\">",
"      Minor LB, Carey JP, Cremer PD, et al. Dehiscence of bone overlying the superior canal as a cause of apparent conductive hearing loss. Otol Neurotol 2003; 24:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/24\">",
"      Mikulec AA, McKenna MJ, Ramsey MJ, et al. Superior semicircular canal dehiscence presenting as conductive hearing loss without vertigo. Otol Neurotol 2004; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/25\">",
"      Chen EY, Paladin A, Phillips G, et al. Semicircular canal dehiscence in the pediatric population. Int J Pediatr Otorhinolaryngol 2009; 73:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/26\">",
"      Picavet V, Govaere E, Forton G. Superior semicircular canal dehiscence: prevalence in a population with clinical suspected otosclerosis-type hearing loss. B-ENT 2009; 5:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/27\">",
"      Belden CJ, Weg N, Minor LB, Zinreich SJ. CT evaluation of bone dehiscence of the superior semicircular canal as a cause of sound- and/or pressure-induced vertigo. Radiology 2003; 226:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/28\">",
"      Welgampola MS, Myrie OA, Minor LB, Carey JP. Vestibular-evoked myogenic potential thresholds normalize on plugging superior canal dehiscence. Neurology 2008; 70:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/29\">",
"      van Heerbeek N, Ingels KJ, Rijkers GT, Zielhuis GA. Therapeutic improvement of Eustachian tube function: a review. Clin Otolaryngol Allied Sci 2002; 27:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/30\">",
"      Seibert JW, Danner CJ. Eustachian tube function and the middle ear. Otolaryngol Clin North Am 2006; 39:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/31\">",
"      Johnson D, Chandrasekhar SS, Mautone AJ. Intranasal phenylephrine-surfactant treatment is not beneficial in otitis media with effusion. Int J Pediatr Otorhinolaryngol 2008; 72:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/32\">",
"      Griffin GH, Flynn C, Bailey RE, Schultz JK. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database Syst Rev 2006; :CD003423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/33\">",
"      Shapiro GG, Bierman CW, Furukawa CT, et al. Treatment of persistent eustachian tube dysfunction in children with aerosolized nasal dexamethasone phosphate versus placebo. Ann Allergy 1982; 49:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/34\">",
"      Aynali G, Yarikta�� M, Yasan H, et al. The effects of methylprednisolone, montelukast and indomethacine in experimental otitis media with effusion. Int J Pediatr Otorhinolaryngol 2011; 75:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/35\">",
"      Arick DS, Silman S. Nonsurgical home treatment of middle ear effusion and associated hearing loss in children. Part I: clinical trial. Ear Nose Throat J 2005; 84:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/36\">",
"      Perera R, Haynes J, Glasziou P, Heneghan CJ. Autoinflation for hearing loss associated with otitis media with effusion. Cochrane Database Syst Rev 2006; :CD006285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/37\">",
"      Silman S, Arick D. Efficacy of a modified politzer apparatus in management of eustachian tube dysfunction in adults. J Am Acad Audiol 1999; 10:496.",
"     </a>",
"    </li>",
"    <li>",
"     Poe, DS, Kujawaski, O. Endoscopic Diagnosis and Surgery of Eustachian Tube Dysfunction. In: Minimally invasive otological surgery, Silverstein, H, Rosenberg, SI, Poe, DS, Jackson, LE (Eds), Delmar Learning, 2003. p.51.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/39\">",
"      Poe DS, Grimmer JF, Metson R. Laser eustachian tuboplasty: two-year results. Laryngoscope 2007; 117:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/40\">",
"      Poe DS, Hanna BM. Balloon dilation of the cartilaginous portion of the eustachian tube: initial safety and feasibility analysis in a cadaver model. Am J Otolaryngol 2011; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/41\">",
"      Poe DS, Silvola J, Pyykk&ouml; I. Balloon dilation of the cartilaginous eustachian tube. Otolaryngol Head Neck Surg 2011; 144:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/42\">",
"      McCoul ED, Anand VK. Eustachian tube balloon dilation surgery. Int Forum Allergy Rhinol 2012; 2:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/43\">",
"      Dyer RK Jr, McElveen JT Jr. The patulous eustachian tube: management options. Otolaryngol Head Neck Surg 1991; 105:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/44\">",
"      Luxford WM, Sheehy JL. Myringotomy and ventilation tubes: a report of 1,568 ears. Laryngoscope 1982; 92:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/45\">",
"      Bluestone CD, Cantekin EI. \"How I do it\"--otology and neurotology. A specific issue and its solution. Management of the patulous Eustachian tube. Laryngoscope 1981; 91:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/16/8458/abstract/46\">",
"      Ya&ntilde;ez C, Pirr&oacute;n JA, Mora N. Curvature inversion technique: a novel tuboplastic technique for patulous Eustachian tube--a preliminary report. Otolaryngol Head Neck Surg 2011; 145:446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14608 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-A2ED1F3088-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8458=[""].join("\n");
var outline_f8_16_8458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2343047\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342820\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342827\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11700761\">",
"      NORMAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11700640\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342881\">",
"      Pressure dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2344336\">",
"      Impaired protective function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2344353\">",
"      Impaired clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342888\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342897\">",
"      Dilatory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342904\">",
"      Patulous dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342911\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342918\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342934\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H964211772\">",
"      Nasal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342948\">",
"      Audiometric evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344874929\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342969\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342997\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2343018\">",
"      Dilatory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1596840563\">",
"      - Underlying etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2344641\">",
"      - Medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2344648\">",
"      - Surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2343040\">",
"      Patulous dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1596840742\">",
"      - Underlying etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2344692\">",
"      - Medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2344699\">",
"      - Surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596840350\">",
"      SEQUELA AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531862\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531869\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531876\">",
"      Tympanic membrane perforations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14531883\">",
"      Cholesteatomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2344727\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2343047\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14608|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/39/30328\" title=\"figure 1\">",
"      Adult ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/47/38644\" title=\"figure 2\">",
"      Difference in the angle of the eustachian tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/58/29604\" title=\"figure 3\">",
"      Anatomy of the eustachian tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14608|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/37/44624\" title=\"picture 1\">",
"      Normal endoscopic view of closed eustachian tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/24/30080\" title=\"picture 2\">",
"      Normal endoscopic view of open eustachian tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/62/40942\" title=\"picture 3\">",
"      Dilatory eustachian tube dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/10/33952\" title=\"picture 4\">",
"      Patulous dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/14/5345\" title=\"picture 5\">",
"      Normal tympanic membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/49/19217\" title=\"picture 6\">",
"      Retracted tympanic membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/6/20576\" title=\"picture 7\">",
"      TM air fluid level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/0/4098\" title=\"picture 8\">",
"      TM atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/54/21344\" title=\"picture 9\">",
"      Early congenital cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/15/27888\" title=\"picture 10\">",
"      TM perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/53/39774\" title=\"picture 11\">",
"      Pneumatic otoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/60/1999\" title=\"picture 12\">",
"      Palpation of internal pterygoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/56/40834\" title=\"picture 13\">",
"      Balloon dilation of eustachian tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/26/28064\" title=\"picture 14\">",
"      Patulous eustachian tube catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14608|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/4/34895\" title=\"movie 1\">",
"      Normal TM mobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/56/22415\" title=\"movie 2\">",
"      Impaired TM mobility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=related_link\">",
"      Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=related_link\">",
"      Evaluation of earache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27925?source=related_link\">",
"      Immunologic treatments for allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=related_link\">",
"      Patient information: Eustachian tube problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7194?source=related_link\">",
"      Temporomandibular joint dysfunction syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_16_8459="Grading IVH by cranial imaging";
var content_f8_16_8459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of intraventricular hemorrhage on cranial ultrasonography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description on parasagittal view",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Germinal matrix hemorrhage only or germinal matrix hemorrhage plus intraventricular hemorrhage less than 10 percent of ventricular area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Intraventricular hemorrhage, 10 to 50 percent of ventricular area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Intraventricular hemorrhage involving more than 50 percent of ventricular area; lateral ventricles are usually distended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Parenchymal bleed in any location and amount",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Papile, LA, et al. J Pediatr 1978; 92:529.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8459=[""].join("\n");
var outline_f8_16_8459=null;
var title_f8_16_8460="Prevalence of stages of CKD in the US";
var content_f8_16_8460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of stages of chronic kidney disease in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        CKD",
"       </td>",
"       <td class=\"subtitle1\">",
"        eGFR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Affected patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 1",
"        </strong>",
"       </td>",
"       <td>",
"        &ge;90 mL/min",
"       </td>",
"       <td>",
"        3.3 percent",
"       </td>",
"       <td>",
"        &asymp;5,900,000",
"       </td>",
"       <td>",
"        Renal injury (eg, proteinuria) without reduced eGFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 2",
"        </strong>",
"       </td>",
"       <td>",
"        89-60 mL/min",
"       </td>",
"       <td>",
"        3.0 percent",
"       </td>",
"       <td>",
"        &asymp;5,300,000",
"       </td>",
"       <td>",
"        Mildly decreased eGFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 3",
"        </strong>",
"       </td>",
"       <td>",
"        59-30 mL/min",
"       </td>",
"       <td>",
"        4.3 percent",
"       </td>",
"       <td>",
"        &asymp;7,600,000",
"       </td>",
"       <td>",
"        Moderately decreased eGFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 4",
"        </strong>",
"       </td>",
"       <td>",
"        29-15 mL/min",
"       </td>",
"       <td>",
"        0.2 percent",
"       </td>",
"       <td>",
"        &asymp;400,000",
"       </td>",
"       <td>",
"        Severely decreased eGFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 5",
"        </strong>",
"       </td>",
"       <td>",
"        &lt;15 mL/min",
"       </td>",
"       <td>",
"        0.3 percent",
"       </td>",
"       <td>",
"        &asymp;500,000",
"       </td>",
"       <td>",
"        Kidney failure, mostly indication for renal replacement therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The estimation of affected patients refers to the US population.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8460=[""].join("\n");
var outline_f8_16_8460=null;
var title_f8_16_8461="Esophageal acid methacholine";
var content_f8_16_8461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal acid increases methacholine responsiveness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 243px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Provocative doses of methacholine causing a 20 percent decrease in FEV",
"    <sub>",
"     1",
"    </sub>",
"    (PD20) in five asthmatics during esophageal infusion of NaCl and HCl infusion (open and closed symbols for patients without and with GE reflux, respectively). The change in PD20 is shown for each subject.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : Forced expiratory volume in one second",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Herve P, Denjean A, Jian R, et al, Am Rev Respir Dis 1986; 134:986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8461=[""].join("\n");
var outline_f8_16_8461=null;
var title_f8_16_8462="Oxygen allows less ventilation";
var content_f8_16_8462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supplemental oxygenation and minute ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Calculated alveolar PO2 (PAO2, blue and green solid lines) and arterial PCO2 (PaCO2, red dashed line) as a function of alveolar ventilation in patients undergoing mechanical ventilation. Calculated PAO2 is shown for two levels of inspired oxygen concentration. For an FiO2 of 0.21 (blue) and alveolar ventilation of 3.6 L/min, the predicted PAO2 is 100 mmHg (point A) and the PaCO2 is 40 mmHg (point A'). When FiO2 is 0.30, alveolar ventilation can be reduced to 1.6 L/min, while maintaining the PAO2 at 100 mmHg (point B). The corresponding PaCO2 at this level is 192 mmHg (point B'). The rate of carbon dioxide excretion (VCO2) is set at 200 mL/min for all calculations. The vertical line through A and A' indicates normal values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Bidani, A, Tzouanakis, AE, Cardenas, VJ, et al, JAMA 1994; 272:957.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8462=[""].join("\n");
var outline_f8_16_8462=null;
var title_f8_16_8463="Esophageal adenocarcinoma endosc";
var content_f8_16_8463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearance of an esophageal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy revealed a fungating mass in the distal esophagus extending from the gastroesophageal junction with complete obstruction of the distal esophageal lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_16_8463=[""].join("\n");
var outline_f8_16_8463=null;
